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INTRODUCTION 
Child presenting with chronic abdominal pain is one of the most 
commonly encountered symptom. The exact prevalence of chronic abdominal 
pain is not exactly known, but the literature reports that 13% of middle school 
children and 17% of high school children experience weekly abdominal pain 
and this accounts for about 2% to 4% of all pediatric office visits 
(1)
. Chronic 
abdominal pain and recurrent abdominal pain terms are used interchangeably. 
The definition of “chronic” is from definition by Apley of recurrent 
paroxysmal abdominal pain in children between the ages of 4 and 16 years that 
persists for greater than 3 months duration and affects normal activity 
(2)
. At 
least as many children experience chronic pain but maintain normal activity 
and rarely come to the attention of the physician 
(3,5)
. The Pediatric Rome group 
has subcategorized the chronic abdominal pain based on clinical presentation:  
(1) Isolated paroxysmal abdominal pain,  
(2) Abdominal pain associated with symptoms of dyspepsia, 
(3) Abdominal pain associated with altered bowel pattern, and  
(4) Abdominal migraine 
(6).
 
Chronic abdominal pain in children is either organic or inorganic. An organic 
cause was found in 70 (82.4%) patients and non-organic cause identified 
(NORAP) in 15 (17.6%) cases. Giardiasis was the commonest organic cause in 
57 (67.0%) cases, either alone or with other parasitic infestations including 
ascariasis, trichuriasis and enterobiasis
(7)
. Cohort studies from India and 
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Pakistan suggest that RAP is most likely to have an organic cause (up to 82% 
of cases), with giardiasis being the most common underlying condition 
(7, 8)
. 
However, another Indian cohort and a Sri Lankan cohort showed that non-
organic RAP is more prevalent (74% and 76%, respectively) 
(9, 10)
. In Malaysia, 
both urban and rural population-based cohorts had a similar prevalence of RAP 
at 9.6% and 11%, respectively 
(11, 12)
.  
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OBJECTIVE 
PRIMARY OBJECTIVE: 
To know whether gallbladder dysmotility constitutes in children with 
chronic abdominal pain  
SECONDARY OBJECTIVE: 
To find out any associating factors for children with chronic abdominal 
pain 
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MATERIALS AND METHODS 
Setting:  
Place of Study: 
 The study was done in the department of Pediatrics, PSG Institute of 
Medical Sciences and Research, Coimbatore. Cases were recruited from 
Pediatric out patient department, PSG Hospitals, Coimbatore. PSG Hospitals is 
a nine hundred bedded multispecialty ISO and NABH accredited teaching 
hospital that offers comprehensive tertiary level health care for patients with 
various ailments and from many nearby districts of western part of Tamilnadu. 
Study Design: 
 The study is a case-control type, where children who fulfilled the 
clinical criteria for chronic abdominal pain were compared with age and sex 
matched controls.  The cases were children between 5 to 15 years of age, who 
were brought to the Pediatric OPD with abdominal pain and fulfilled the 
inclusion criteria. After enrollment of the cases, healthy age and gender-
matched controls were subjected into the study.  
Time Frame: 
The study was conducted for one year i.e. from 1
st
January 2016 to 31
st
 
August 2017. 
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SAMPLE SIZE:  
Thirty cases with chronic abdominal pain and an equal number of 
healthy controls were included in the study. 
INCLUSION CRITERIA: 
 Children of both gender aged between 5 to 15 years of age with 
chronic abdominal pain according to ROME III criteria. 
 Healthy children, with no clinical evidence of any chronic illness 
or on medications were recruited as controls. 
EXCLUSION CRITERIA: 
 Non consent 
 Children with past abdominal surgical history or known chronic 
abdominal pathology  
 Children who had obvious causes for chronic abdominal pain 
following ultrasonographic examination of the gallbladder. 
 Children who could not tolerate or cannot complete the fatty 
meal. 
METHODOLOGY: 
 Children from 5 to 15 years of age attending Pediatrics out patient 
department for chronic abdominal pain were requested to respond to a 
questionnaire based on the ROME III criteria. Child fulfilling ROME III 
criteria for chronic abdominal pain were included in the study after obtaining 
an informed consent from parents and children, if they could assent for the 
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study. The cases were subjected to ultrasonographic examination of the 
gallbladder after a fasting of at least 6 hours. Following the baseline ultrasound 
study, the subjects were instructed to eat a fatty meal. The fatty meal is a 
special diet prepared by our hospital dietician according to basis of their fat 
quantity required to produce gallbladder contraction. The standard meal 
contained fat ranging from 30 to 70 g and quantity of fat was decided according 
to child's age. Following the fatty meal the subjects were subjected to a second 
ultrasonographic examination of the gallbladder to assess for gall bladder 
contractility.  
 During ultrasonographic examination of the gallbladder, the greatest 
length (L), greatest transverse width (W), and greatest anteroposterior diameter 
(A) of the gallbladder was measured in the fasting state and postprandial period 
of 30min. Dodd‟s Formula was used to measure the gall bladder volume. 
                                       Volume (V) (cm
3
) = 0.52 × L × W × A 
  The gallbladder ejection fraction (EF) for each examination was 
obtained from two-volume data using the following equation. Where V0 = 
gallbladder volume before the test meal, Vn = gallbladder volume after the test 
meal. 
EF (%) = ((Vo-Vn) / Vo) X 100% 
Children with ejection fraction of less than 40% were considered to have 
gallbladder dysmotility 
(182)
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FLOW CHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Children with chronic abdominal pain and children for routine USG 
abdomen 
USG abdomen after 6 hours of fasting 
Statistical analysis between children with chronic abdominal pain and  
healthy age matched controls 
Gallbladder volume and Ejection fraction 
USG abdomen 30 min following fatty meal 
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Statistical Analysis: 
 The statistical analysis was done using SPSS software (statistical package 
for the social science version-19).  
1. The Independent studentst test was applied to compare the means of 
quantitative data. 
Values were expressed as Mean ± SD. The p values were interpreted 
as shown below 
a. p> 0.05 was considered not significant.  
b. p< 0.05 was considered statistically significant.  
 
2. The ejection fraction of the cases was correlated with their BMI for any 
possible association using Pearson‟s correlation analysis 
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REVIEW OF LITERATURE 
Gallbladder – The gallbladder is a thin-walled sac, placed between both 
hepatic lobes. It is divided in to three parts anatomically. It is the fundus, 
corpus, and infundibulum
 (13)
.Anatomically the human gallbladder and 
gallbladder of most mammalian species dogs, cats, guinea pigs, and mice are 
fairly similar. The gallbladder ends with cystic duct. Cystic duct has a diameter 
of 7 mm with amucosa containing spiral valves (valves of Heister). The cystic 
duct then drains into the common bile duct and there is no sphincteric structure. 
The course of common bile duct is through the head of thepancreas ending in 
the sphincter of Oddi.  
Figure 1: Structure of gallbladder 
Now sphincter of Oddi and common bile duct penetrates theduodenal wall to 
form the ampulla of Vater. Cystic duct or the common bile duct has no 
peristaltic motility. 
10 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Sphincter of Oddi 
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Figure 3: Gallbladder histology 
Gallbladder Histology – it consists of mucosa with a single layer of epithelial 
cells, a lamina propria, a single layer of muscle that resembles the muscularis 
mucosa of the gastrointestinal tract, and a serosal layer
 (14)
.  
Concentration of hydrophobic bile salts is done by epithelial layer by 
absorbing water and electrolytes. Small quantities of bile salts and chloride are 
transported by passive diffusion by mucosal layer 
(15, 16)
. Hydrophobic bile salts 
are aggressive against stomach, esophagus etc. but the epithelial cells tolerates 
it by its cytoprotective with help of prostaglandin E2 (PGE2). Epithelial cells 
are covered by mucin, which is secreted by prostaglandin and this prevents 
damage by inactivating bile salt induced free radicals. Vagus and splanchnic 
nerves innervate the muscular layer and this synapses with intramural neurons. 
In the fasting and digestive phase of biliary tract, it is integrated with by 
neurohormonal mechanism of the digestive tract 
(14)
. The bile is continuously 
secreted by liver in to intrahepatic and from there it flows in to extra hepatic 
ducts. Sphincter of Oddi (SO) helps the gallbladder to fill with bile, which is 
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then stored and concentrated in the fasting state. And during all three phases of 
digestive periods the concentrated bile is emptied. Only about 10% of the 
hepatic bile drain in to the duodenum during the interdigestive period that is 
during intervals between the phasic contractions of the sphincter of Oddi 
(diastolic periods). This occurs when sphincter of Oddi basal pressure is 
exceeded by the ductal pressure
(17)
. It is the remaining 90% bile that is 
redirected towards the cystic duct and gets stored in the gallbladder. By passive 
and active mechanisms the gallbladder distends with entry of bile. Active 
relaxation or accommodation of the gallbladder is mediated by adrenergic and 
noncholinergic nonadrenergic nerves it is gradually induced by the incoming 
bile. The vagus and splanchnic nerves and the hormone cholecystokinin (CCK) 
are the main neurohormonal mechanisms regulating the motility of the 
gallbladder 
(18–20)
. The efferent and afferent fibers are from vagus nerve 
(21)
. The 
eﬀerent fibers form as preganglionic neurons and synapse to intramural 
postganglionic cholinergic neurons. The intramural postganglionic neurons are 
present within the wall of the gallbladder. Gallbladder contraction is stimulated 
by efferent fibers of vagus nerve,hexamethonium and atropine are muscarinic 
receptor antagonist that acts by ganglionic blocker. Gallbladder relaxes by 
splanchnic nerve stimulation and propranolol blocks this relaxation 
(22)
.  
Atropine treated cat gallbladder muscle strips demonstrated the inhibitory 
innervation
 (23)
. The strips blocked by propranolol were stimulated by electrical 
field, there was relaxation the strips in response to electrical field stimulation 
but was unaﬀected by partial antagonists of the vasoactive intestinal peptide 
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(VIP) suggesting that the stimulus was acting on sympathetic postganglionic 
neurons releasing epinephrine as the neurotransmitter that act primarily on 
beta-adrenergic receptors. However, diﬀerent results were obtained when the 
atropine-treated cat gallbladder was relaxed by stimulating the vagus nerve. 
Under these experimental conditions the relaxation was resistant to propranolol 
but was abolished by pretreatment with an antiserum against VIP suggesting 
that this peptide is the neurotransmitter responsible for it 
(24)
. It is conceivable 
that the VIP antiserum is a more eﬀective antagonist against VIP than the 
partial VIP antagonists that were used in muscle strips. These discrepancies 
between in vitro and in vivo studies cannot be fully explained at this time 
although it is possible that both neurotransmitters are involved in the 
gallbladder relaxation. Further studies are needed to reconcile these diﬀerent 
observations that were demonstrated using diﬀerent experimental conditions. 
During the fasting period the gallbladder maintains a moderate tonic 
contraction that is superimposed with nonpropulsive and propulsive 
contractions 
(25, 26)
. These tonic and rhythmic contractions were demonstrated in 
dogs in vivo. The nonpropulsive contractions are probably designed to keep the 
bile insoluble constituents in solution preventing their precipitation, 
particularly precipitation of cholesterol that can lead to gallstone formation. 
These contractions are even observed in muscle strips from normal human 
gallbladders 
(26)
. The propulsive contractions empty fractions of gallbladder 
bile contributing to the small percentage of bile that enters the duodenum 
during this interdigestive period. These contractions also occur in the fasting 
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period during the migrating motor complex that is known to stimulate the 
gallbladder motility. The increased number of gallbladder contractions 
coincides with the phase 3 of the antral migrating motor complex and with the 
phase 2 of the duodenum 
(27)
. Thesecontractions are responsible for the 
additional albeit small discharge of gallbladder bile in the duodenum that takes 
place during this period.In the digestive period strong gallbladder contractions 
and sphincter of Oddi relaxation lead to the high rates of bile discharge ﬂowing 
into the common bile duct and duodenum.During this period, the gallbladder 
motor activity like the rest of the gastrointestinal tract is inﬂuenced by the three 
phases of digestive process: cephalic, antral, and duodenal 
(28)
. The cephalic 
phase is initiated by stimuli that activate the central nervous system, as 
individuals are exposed to olfactory, visual, and the taste of food. This phase is 
mediated by preganglionic vagal fibers that synapse with postganglionic 
cholinergic neurons. It is estimated that as much as 30–40% of the gallbladder 
bile may be emptied during this phase. Once food reaches the stomach it 
triggers an antral-gallbladder reﬂex also mediated by vagal fibers. The 
gallbladder emptiesmost of its remaining contents during the intestinal phase 
induced by the release of CCK from the duodenum and proximal jejunum 
(29)
. 
Duodenal CCK contracts the gallbladder mostly by acting directly on 
cholinergic neurons 
(18)
 and like with the pancreas, and it may also activate long 
reﬂexes through the vagus nerve. Meals containing proteins and fats act on 
duodenal CCK containing endocrine cells that stimulate vagal sensory fibers 
followed by activation of preganglionic and postganglionic cholinergic neurons 
15 
 
(30)
. Either mechanism stimulates the final pathway of postganglionic 
cholinergic neurons, since atropine pretreatment blocks the gallbladder 
contraction induced by physiological concentrations of CCK- 8 
(31)
 or by a 
protein-fatty meal. CCK-1 receptors are alsopresent in the gallbladder muscle, 
but they only can be stimulated by pharmacological concentrations of CCK, 
since they are not blocked by either atropine or tetrodotoxin. 
Functional GB Disorder 
Definition: 
Gallbladder dysfunction is a motility disorder of the GB that manifests 
symptomatically with biliary pain as a consequence of either an initial 
metabolic disorder (i.e., supersaturated bile with cholesterol)
(32)
 or a primary 
motility alteration of the GB in the absence, at least initially, of any 
abnormalities of bile composition
(33)
. It is likely that the latter condition, by 
causing bile stasis, may alter over a period of time, bile recycling 
and bile composition within the GB. Both conditions may eventually lead, over 
a period of time, to thedevelopment of organic abnormalities (example 
gallstones and acute cholecystitis). The symptoms of these organic and 
functional conditions appear to be indistinguishable from one another, and 
therefore their differential diagnoses require a careful diagnostic workup. 
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Epidemiology: 
  The prevalence of GB dysfunction is not known. Large population-
based studies have reported that prevalence of biliary pain in ultrasonography 
(USG)-negativesubjects with GB in situ varies from 7.6% in men to 20.7% in 
women 
(34,35)
. 
Clinical Presentation: 
 The most specific symptom attributed to functional disorders of the GB 
appears to be biliary pain, and therefore the crucial steps in the diagnosis are a 
thorough history supported by objective evidence of GB dysfunction and 
exclusion of structuralabnormalities. These patients will need to be evaluated 
with longer follow-ups for at least 1 year after cholecystectomy.  
Criteria for this diagnosis: 
1. Absence of gallstones, biliary sludge, or microlithiasis 
2. An abnormal GB ejection fraction of less than 40% by using a 
continuous intravenous cholecystokinin octapeptide infusion over 
a 30-minute period 
3. A positive therapeutic response with absence of the recurrent pain 
for longer than 12 months after cholecystectomy 
Laboratory and Instrumental Investigations: 
The symptoms of GB dysfunction must be differentiated from organic 
disease and other more common functional disorders including functional 
dyspepsia and IBS in which symptoms do occur daily for at least short 
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intervals (few days or weeks). Tests of liver biochemistries and pancreatic 
enzymes should be obtained in those patients with the previously mentioned 
symptomatic criteria. These tests are normal in the presence of GB motility 
dysfunction. The findings of abnormal liver or pancreatic enzyme levels or 
both indicate that other diagnoses should be considered.  
Ultrasound: 
 Transabdominal ultrasonographic study of the entire upper abdomen is 
mandatory in patients with the previously mentioned symptoms. In the 
presence of GB dysfunction, the biliary tract and pancreas appear normal on 
USG. In particular, gallstones or sludge cannot be shown. USG usually detect 
stones within the GB equal to or greater than 3 to 5 mm in diameter, but it has a 
low sensitivity to detect smaller stones
 (36)
. USG detection of stones or sludge 
within the common bile duct is even more difficult. Endoscopic USGis more 
sensitive than traditional transabdominal USG in detecting microlithiasis (tiny 
stones 3 mm) and sludge within the biliary tract
 (37)
. 
Endoscopy: 
In the presence of normal laboratory and ultrasonographic findings, an 
upper gastrointestinal endoscopy is usually indicated. The diagnosis of GB 
dysfunction is suspected in the absence of significant abnormalities in the 
esophagus, stomach, and duodenum. 
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Microscopic bile examination: 
 To exclude microlithiasis as a cause for these symptoms, a careful 
microscopic examination of GB bile could be performed. The detection of 
microlithiasis and cholesterol microcrystals is best accomplished by a careful 
examination of GB bile obtained directly at the time of ERCP or by aspiration 
from the duodenum during endoscopy after cholecystokinin (CCK) stimulation. 
The resultant bile should appear deep golden yellow to dark green-brown. Pale 
yellow bile from the common duct is not appropriate. Evenin those patients 
with cholesterol gallstones or sludge, this hepatic bile is often free of 
cholesterol microcrystals being insufficiently concentrated to nucleate. The 
collected bile should be immediately centrifuged and examined.  
Two types of deposits may be evident 
1. Cholesterol crystals and/or  
2. Calcium bilirubinate granules. 
Cholesterol microcrystals are birifringent and rhomboid shaped and best 
visualized by polarizing microscopy. The presence of cholesterol crystals 
provides a reasonably high diagnostic accuracy for microlithiasis
 (38-40)
. 
Bilirubinate granules are red-brown and can be detected by simple light 
microscopy. These crystals are significant only in freshly analyzed bile. 
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TESTS OF GB MOTOR DYSFUNCTION 
Assessment of GB emptying by cholescintigraphy: 
Cholescintigraphy is performed after the administration of technetium 
99m–labelled iminodiacetic acid analogs. These compounds have a high 
affinity for hepatic uptake, are readily excreted into the biliary tract, and 
concentrated in the GB. The net activity-time curvefor the GB is then derived 
from subsequent serial observations, after either CCK administration or the 
ingestion of a meal containing fat. GB emptying is usually expressed as GB 
ejection fraction, which is the percentage change of net GB counts after the 
cholecystokinetic stimulus. A low GB ejection fraction has been considered 
evidence of impaired GB motor function that, in the absence of lithiasis, could 
identify patients with primary GB dysfunction. The most widely used and 
validated stimulus to contract the GB has been the slow intravenous infusion of 
CCK analogs, especially CCK-8 over a 30-minute period 
(41, 42)
. Fatty meals 
and variable bolus injections of CCK do not yield consistent results. Reduced 
emptying can arise from either impaired GB contraction or increased resistance 
of the SO because of an elevated basal tone. Furthermore, several other 
conditions that do not necessarily present with biliary pain can be associated 
with reduced GB emptying such as obesity, diabetes, and several drugs 
(example - calcium channel antagonists and oral contraceptives). An accurate 
medical history should exclude secondary causes of impaired GB motility. Two 
systematic reviews that did not discriminate between slow and rapid 
intravenous infusion of CCK have concluded that there is no sufficient 
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evidence to recommend the use of CCK cholescintigraphy to select patients for 
cholecystectomy
(43, 44)
. 
Assessment of volume changes by transabdominal real-time US: 
Unlike cholescintigraphy, this method measures GB volume and obtains 
serial measurements during fasting or after a meal or the intravenous infusion 
of CCK analogs. In addition, US allows for assessment of residual volume after 
emptying and the rate of refilling after GB contraction. 
US may be helpful when radiation should be avoided. One deficiency in 
the technique is the fact that it is operator dependent, and the results may not be 
reproducible between different centers; therefore, the diagnostic role, if any, of 
ultrasonographic assessment of GB emptying has not become the standard in 
GB dysfunction. Further prospective randomized studies are needed to better 
understand the predictive value of CCK cholescintigraphy or CCK USGto 
recommend cholecystectomy in patients with suspected GB motility 
dysfunction. 
Pain provocation test: 
A stimulation test with CCK attempting to duplicate biliary pain has 
been historically used as a diagnostic investigation. This test has low sensitivity 
and specificity in selecting patients with GB dysfunction who respond to 
therapy. This may relate to problems in the subjective assessment of pain and 
the use of bolus injections of CCK. The latter can induce pain by stimulating 
intestinal contractions. 
21 
 
 
Figure 4:Algorithm of the diagnostic workup and management of 
functional GB disorders. 
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FUNCTIONAL ABDOMINAL PAIN 
Introduction:  
Apley and Naish described chronic abdominal pain as children presenting with 
intermittent episodes of abdominal pain occurring for at least 3 months without 
any identifiable cause and interfering with day to day activities
(3)
. The term 
„chronic abdominal pain‟ is often used interchangeably with „recurrent 
abdominal pain‟. Abdominal pain that is continuous, persistent, or intermittent 
over a period of a few months is called as chronic abdominal pain. The pain 
varies in intensity. There may be asymptomatic periods interposed with  painful 
periods gradually the duration of painful periods prolong, generating a 
condition that profoundly causes distresses in the daily life of children. The 
term recurrent abdominal pain represents a symptom and not a diagnosis. Many 
conditions can cause abdominal pain that is recurrent, but most children and 
adolescents presenting with this symptom have a functional disorder without 
any evidence of organic disease. They are considered to have functional 
abdominal pain. 
Epidemiology: 
 Chronic abdominal pain is a common pediatric complaints 
(45)
, 
accounting for 2–4% all of pediatric hospital visits (46). Symptoms consistent 
with irritable bowel syndrome (IBS),occur in 14% of all high-school students 
and 6% of all middle-school students 
(5)
. IBS is much more prevalent than other 
medical conditions such as hypertension, asthma and diabetes that tend 
toreceive greater attention 
(47)
.Patients with IBS do not seek medical attention, 
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assessing the prevalence of IBS is often difficult. Only one in four patients with 
symptoms of IBS seek medical care 
(48)
.Reports from Kenya, Poland, Russia, 
India and Pakistan reveal that, functional abdominal pain is probably a 
universal problem 
(10, 49-51)
. A Malaysian study in 1500 schoolchildren found 
evidence of chronic abdominal pain in 10% of children, concluding that, in 
spite of differences in diet, customs and culture, the overall prevalence of this 
entity was similar across regions
(52)
. A Danish study demonstrated that 15% of 
children aged 9–12 years had recurrent abdominal pain(53).Quality of life in 
individuals with IBS is substantially poorer than in general population 
(54)
.  
Physiology of the gastrointestinal pain response:  
 Visceral pain perception passes through a complex pathway of 
peripheral and central nervous structures that signal, relay and modify the 
afferent stimulus. The enteric nervous system (ENS) is arranged into two main 
plexuses providing the intrinsic innervation of the gut. This forms a continuous 
network around the circumference of the wall of the intestine along its length. 
The mesenteric plexus, alsocalled as Auerbach‟s plexus, is located between the 
external longitudinal and internal circular muscle layers, and the submucosal 
plexus (Meissner‟s plexus) lies in between the circular muscle layer and the 
mucosa. The mesentericplexus is larger and projects fibers mainly to the 
smooth muscle of the gut and it controls the motility. Meanwhile, the 
submucosal plexus projects into the mucosa and submucosa and control the 
glandular secretion. The two intestinal plexuses are connected to each other by 
interconnections which bind the two networks into a functionally unified 
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nervous system. The characteristics of this mesh of sensory fibers, interneurons 
and motor neurons, enables this mini-brain or „gut brain‟ to integrate the 
sensory information, and to organize the motor and secretory responses and 
influence the luminal absorption, thereby producing a functional state that is 
adapted to the well-being of the individual. The ENSthough it receives input 
from the central and autonomic nervous systems, it can function independently. 
The ENS performs most of its functions in the absence of central nervous 
system (CNS) control, locally integrating the information of intrinsic afferent 
fibers (for example, luminal distension and chemical stimuli) with efferent 
axons, resulting in motor reflexes or secretory or absorptive responses. The 
extrinsic nervous system functions to consist connecting the ENS with the 
CNS. This communication allows the CNS continuously to integrate the 
information from the gastrointestinal tract with incoming information from 
other organs and from the environment. Under physiological conditions, most 
of these do not reach the level of conscious perception.21 However, sensations 
that trigger a particularbehavior, including hunger, satiety and need to defecate, 
reach the conscious perception by reaching the cortex. The constant influenceof 
the CNS on the ENS through activation of a subset of vagal and sacral 
parasympathetic fibers is responsible for psychological stress and 
gastrointestinal response, manifested clinically by the occurrence of vomiting 
or diarrhea in patients experiencing a stressful event.  
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 The ENS and the brain use multiple neurotransmitters for exchanging of 
inhibitory or excitatory information. They include excitatory neurotransmitters 
such as acetylcholine and substance P, and gut inhibitory neurotransmitters 
such as nitric oxide, ATP, vasoactive intestinal peptide (VIP), cholecystokinin, 
enkephalins, calcitonin gene-related peptide (CGRP), norepinephrine 
(noradrenaline), epinephrine (adrenaline) and others. Neurotransmitters such as 
serotonin (5-hydroxytryptamine) and histamine have more complex effects. 
Ninety-five per cent of the total body 5-HT lies within the gut. Of the total gut 
5-HT, 90% is found in the granules of the enteroendocrine cells, and 10% in 
the neurons of the myenteric plexus
 (55, 56)
. 5 HT also plays an important role in 
regulating GI motility and intestinal secretion
(55)
. 5-HT receptors appear to 
participate in mucosal sensory processing within the gut. Distension and 
stroking of mechanosensitive receptors in the enteroendocrine cells triggers the 
release of 5-HT 
(57)
. There are at least seven main classes of 5-HT receptor and 
22 subclasses that can be differentiated on the basis of structure and function. 
Four classes have been reported in the human GI tract (5-HT1, 5-HT2, 5-HT3 
and 5-HT4)
(58)
. Serotonin action is complex, with mixed effects ranging from 
smooth muscle contraction, to relaxationthrough stimulation of inhibitory nitric 
oxidereleasing neurons. Higher levels of serotonin are present in diarrhea-
predominant IBS 
(59)
. The ENS has the ability to modulate signal transduction 
by enhancing or inhibiting the activation of nociceptors through alteration in 
smooth muscle tone and contractile activity. Visceral pain may be modulated 
also at the CNS level by emotional or cognitive factors, providing a rationale 
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for the use of centrally acting agents or cognitive behavioral treatments in 
functional bowel disorders. Neuroimaging studies have provided information 
on differences in brain processing of visceral stimuli between normal 
individuals and those suffering from IBS, revealing an increased activity at the 
level of the anterior cingulated cortex, prefrontal cortex, insular cortex and 
thalamus (the areas associated with emotional responses) in patients with IBS 
compared to asymptomatic individuals
( 60-62)
. 
Pathophysiology: 
 Several hypotheses have been put forward to explain the cause of 
functional recurrent abdominal pain. We examine them in the following 
sections. 
Visceral hyperalgesia: 
 The visceral hyperalgesia hypothesis proposes that greater sensitivity of 
visceral afferent pathways or central amplification of visceral input lead to an 
enhanced perception of visceral stimuli. There is evidence that the pain and 
discomfort of IBS might be due to hyperalgesia and allodynia of the gut. While 
in hyperalgesia a painful stimulus is perceived as even more painful, in 
allodynia a non-painful stimulus becomes painful 
(63)
. Anoxious stimulus 
applied to a particular area of thegut may sensitize primary afferent fibers and 
nociceptors of adjacent areas, causing painful sensations with a low-intensity 
stimulus, resulting in primary hyperalgesia. Most IBS patients experience rectal 
discomfort at lower intraluminal volumes or pressures
(64, 65)
 and have 
diminished tolerance to intestinal gas 
(66)
. Trimble et al
(64)
 found that patients 
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presenting with one functional bowel disorder frequently had additional 
symptoms referable to other parts of the digestive system, suggesting that 
enhanced visceral nociception may be a pan-intestinal phenomenon. For 
example, it has been reported that in addition to the features of rectal 
hyperalgesia, IBS patients have a decreased sensory threshold to balloon 
distension of the esophagus. Children with functional abdominal pain exhibited 
generalized visceralhyperalgesia, whereas IBS patients had rectal but not 
gastric hyperalgesia
(65)
.Different GI symptoms were reproduced by stimulation 
of the predominant site of hyperalgesia, providing a physiological explanation 
of symptoms in children who have distinct phenotypic presentations.  
Dysmotility:  
 In addition to a greater intestinal sensitivity, patients with functional 
bowel disorders may display abnormal motility. Various types of motor 
disturbances have been documented in IBS, apparently reflecting dysfunction 
at one or more levels of the brain–gut axis(67). Although the pathophysiology of 
IBS is commonly attributed to dysfunction of the large intestine, evidence 
exists to incriminate the small bowel as well 
(68)
. Postprandial motor 
dysfunction in the small bowel appears to be more prevalent among IBS 
patients who exhibit underlying visceral hypersensitivity in the fasting state. 
Abdominal cramping has been associated with the passage of high-amplitude 
contractions through the ileocecalregion
(69)
. Bloating has been explained by an 
abnormal transit and pooling of gas in conjunction with guthypersensitivity
(66)
. 
Manometric studies have demonstrated postprandial antral hypomotility in 
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children and adults with functional dyspepsia
(70)
. However, not all studies have 
demonstrated differences between patients and control subjects
(71, 72)
. Motility 
changes in IBS are neither specific nor predictable and do not serve as a 
diagnostic marker or as an aid to the selection of treatment
(73)
. It has been 
suggested than, rather than having a persistent motility abnormality, patients 
with functional bowel disorders exhibitan abnormal motor response to a variety 
of physiological stimuli
(74)
. 
Brain–gut interaction: 
 The shortcomings of isolated experimental or observational models in 
explaining the complex nature of functional bowel disorders have led research 
to focus on the alterations in the communications between the CNS and the GI 
tract, hence the term „brain–gut‟ interaction(47, 75). There are multiple examples 
of brain–gut interaction, the most common being the subjects who, under 
emotionally stressful situations, develop diarrhea, nausea or vomiting. Anger 
and aggression increase colonic motility, while hopelessness results in 
decreased motility
(76)
. The brain–gut model links alterations in peripheral 
sensory afferent communication from the gut (e.g. visceral hyperalgesia) 
toCNS processing of the sensory stimuli and its efferent signaling to the gut. In 
IBS patients multiple studies have shown that both gut and brain show an 
exaggerated responsiveness to different stimuli. Patients with IBS have 
significantly greater electroencephalogram (EEG) abnormalities than 
controls
(77)
. Dynamic brain imaging technologies such as positron emission 
tomography (PET) and functional magnetic resonance imaging (fMRI) have 
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recently been applied to the study of the gut–brain axis in order to identify the 
areas of the brain activated by visceral sensations. Studies with these 
techniques have suggested an abnormal cerebral processing of visceral stimuli 
in patients with functional bowel disorders 
(60, 61)
. 
Inflammation: 
 There is evidence that IBS can occur following a gastrointestinal 
infection resulting in transient inflammation. Gwee et al reported that 20–25% 
of patients admitted to the hospital for bacterial gastroenteritis developed 
symptoms consistent with IBS in the first 3 months 
(78)
. Rectal biopsies 
prospectively obtained during and after acute gastroenteritis from patients who 
developed postinfectious IBS and a control group, showed that the former 
group exhibited significantly greater expression of interleukin (IL)-1Beta 
mRNA 
(79)
. A recent study examining full-thickness biopsies from the 
jejunum of patients with severe IBS revealed inflammation and neuronal 
degeneration in the mesenteric plexus, suggesting a possible pathogenic role of 
inflammation 
(80)
.Animal studies also seem to indicate that inflammation may 
produce persistent neuromuscular gut dysfunction
(81)
. Mildmucosal 
inflammation may perturb neuromuscular function also at remote non-inflamed 
sites. The gut dysfunction may persist even after reduction of 
the mucosal inflammation. Substances that mediate these changes are not fully 
understood, but there is growing recognition of the role of serotonin as a 
sensitizing agent. 
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Immunity: 
 The mucosal immune system mediates the clinical impact of stress and 
other psychological factors on the gut. Vagal afferents can be activated by 
products of mast cell degranulation, resulting in sensitization of silent 
nociceptors. Mast cell mediators may be released in response to luminal 
macromolecules, a phenomenon that could explain brain–immune system 
interactions within the gut. A descending input by the vagus nerve may also 
reciprocally affect mast cell degranulation, resulting in local effects on 
secretomotor activity. 
Stressors: 
 Stressful events have long been believed to be important in the 
development of symptoms in functional bowel disorders
(82)
. Physiological 
reactions to stressors should be considered as attempts by the body to adapt – a 
natural coping mechanism, in which, if stressors are not too extreme or long 
standing, the subject is usually successful in reaching a homeostatic state. 
However, at times the body loses the capacity to adapt and deleterious 
behavioral responses may arise. Chronic exposure to threat is associated with 
alterations in theautonomic outflow, resulting in activation of 
thehypothalamic–hypopituitary–adrenal axis with alteration in pain 
modulation. Corticotropinreleasing hormone seems to be the hormonal 
mediator of the stress response. Intracerebroventricularinjection of 
corticotropin releasing factor, which mimics the responses to stress in animals, 
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exacerbates nociceptive responses associated with increased release of 
histamine
(83)
. 
 In humans, possibly as a primitive response to danger, stress induces 
delayed gastric emptying, slower small bowel activity and accelerated colonic 
transit
(84-87)
.These alterations may presumably cause diarrhea, constipation or 
abdominal distension depending on the predominant abnormality. 
Genetics: 
 A recent study showed a significant association between subjects with 
abdominal pain or bowel disturbances and first-degree relatives with IBS 
and dyspepsia
(88)
. Twin studies have shown a 17% concordance for IBS in 
monozygotic patients with only 8% concordance in dizygotic twins. Although 
these data suggest a specific role for heredity in the development of IBS, the 
same study showed ahigher correlation of IBS with parental symptoms, 
suggesting that social learning from the patient‟s environment has an equal or 
greater influence 
(89)
. 
Biopsychosocial model: 
 The biopsychosocial model
(90)
 provides a framework to integrate the 
biological and psychosocial processes, in an attempt to understand the 
underlying pathophysiological mechanisms determining disease susceptibility, 
and to explain the clinical variability and outcome among individuals. The 
biopsychosocial model, proposed as an alternative to the traditional biomedical 
model, conceptualizes the general state of health as resulting from the 
32 
 
integration of medical and psychosocial factors. To understand this model, one 
should differentiate between disease, which is the abnormality of the structure 
and/or function of organs and tissues (physical component), and illness, defined 
as the patient‟s perception of health and bodily dysfunction (psychological 
component). In Engel‟s model (90), illness and disease result from interactions at 
the cellular, tissue, interpersonal and environmental levels resulting in a clinical 
outcome. The biopsychosocial model assumes that genetic influences on 
disease susceptibility and behavior result in a biological and psychosocial 
predisposition that will influence later psychosocial experiences, physiological 
functioning, or susceptibility to a pathological condition. This particular 
background is affected by physical and environmental exposures such as 
infection, food intolerance and social exposures including friends, family and 
community to influence the patient‟s attitude towards illness (91). Stress acting 
on a vulnerable GI tract leads to an imbalance in the system, resulting in an 
alteration of the brain–gut axis. Multiplicity of stressors reinforces and up-
regulates the response. It is well recognized that some IBSpatients report 
initiation or exacerbation of symptoms at times of stress, trauma and major 
loss
(92)
. Traumatic early life events such as child abuse may predispose to 
functional bowel disorders 
(93)
. There have been reports of a greater prevalence 
of sexually and physically abusive experiences in individuals with IBS than in 
patients with organic gastrointestinal disorders and non-patient populations 
(94)
. 
The interaction of the previously described subsystems with psychosocial 
modifiers (concurrent psychiatric diagnosis, life stress, social support, coping 
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mechanisms) affects the behavior of the individual, the biological nature of the 
condition and, ultimately, the clinical outcome. New or uncontrollable 
threatening situations may result in emotional and physiological arousal. 
Psychosocial factors may affect the end result (clinical presentation and 
outcome) acting on gut physiology, modulating symptoms experience, and 
influencing health behavior and therapeutic interventions (Figure 5).The 
relative contribution of the medical and psychosocial factors varies among 
patients. This model should be considered when planning therapy, as failure to 
link the disease and illness components will reduce the likelihood of an 
effective treatment 
 
Figure 5: Proposed pathophysiological model for functional bowel 
disorders. 
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Functional bowel disorders presenting with abdominal pain by ROME III: 
1. Functional dyspepsia 
2. Irritable bowel syndrome 
3. Abdominal migraine 
4. Functional abdominal pain 
5. Childhood Functional Abdominal Pain Syndrome 
Differential diagnosis: 
A number of clinical features („red flags‟) are commonly considered as 
orienting towards an organic etiology, although definitive proof for their 
predictive value is scant. The presence of an isolated symptom (such as isolated 
abdominal pain) is usually thought to be consistent with a functional disorder, 
while multiple symptoms (such as abdominal pain with weight loss, or 
vomiting, or diarrhea) are more likely to be due to an organic condition. There 
are almost endless causes of chronic organic abdominal pain in children.  
Organic causes of chronic abdominal pain: 
Gastrointestinal 
Esophagitis, gastritis, duodenitis, peptic ulcer, eosinophilic gastroenteritis, 
malrotation, cysts (duplication or mesenteric), celiac disease, parasites, 
hernias, tumors, foreign body,  intussusception, inflammatory bowel disease 
Hepatobiliary 
Chronic hepatitis, cholelithiasis, cholecystitis, choledochal cyst, sphincter of 
Oddi dysfunction 
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Pancreatic 
Pancreatitis, pseudocyst 
Respiratory 
Infection, tumor or inflammation vicinity of diaphragm 
Genital 
Hematocolpos, endometriosis, mittelschmertz tumor 
Urinary 
Ureteropelvic junction obstruction, recurrent pyelonephritis, recurrent 
cystitis 
hydronephrosis, nephrolithiasis 
Metabolic 
Porphyria, diabetes, lead poisoning 
Hematological 
Angioedema, collagen vascular disease, sickle cell disease 
Musculoskeletal 
Trauma, inflammation, infection, tumor 
Psychiatric 
Conversion reaction 
 
Peptic disease: 
Pain related to peptic ulcer disease is usually epigastric and non-
radiating, but may also be generalized or periumbilical. It occasionally awakens 
the patient from sleep. It may occur at any time of the day and frequently 
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children experience exacerbation rather than relief with meals. A review of 160 
children concluded that epigastric pain, food-related pain, vomiting, bleeding 
and family history were important factors in the diagnosis of peptic ulcer in 
childhood
 (95)
. However, the clinical presentation of ulcer mayhave symptoms 
that overlap with some functional bowel disorders such as functional 
dyspepsia. A favorable response to antacids or H2 blockers may orient towards 
a peptic disease, but there is evidence that anti-secretory therapy may also be 
effective in dyspepsia. Therefore, as symptoms and therapeutic response may 
be indistinguishable, the definitive diagnosis of peptic disease requires 
esophagogastroduodenoscopy 
(96)
. While it is accepted that H. pylori infection 
causes both gastritis and duodenal ulcer disease, its etiologic role in functional 
dyspepsia is still controversial. Dyspepsia associated with epigastric pain was 
frequently found in preschool and school children infected by H. pylori
(96, 
97)
.These findings are contradicted by other reports. A German study concluded 
that H. pylori infection in children was mostly asymptomatic and not associated 
with specific gastrointestinal symptoms 
(98)
. A review of 2715 children with H. 
pylori infection found abdominal pain in 5–17% of cases. However, abdominal 
pain was also found in 5–29% ofpatients without H. pylori infection (99). 
Universal testing or treatment of H. pylori infection in children with either 
recurrent pain referable to the epigastrium or recurrent periumbilical abdominal 
pain is currently not recommended. 
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Pancreatitis: 
Pain resulting from pancreatic inflammation is usually epigastric, 
radiating to the sides or back, with pain episodes frequently triggered or 
aggravated by meals. Nausea and vomiting are often present. Severe abdominal 
tenderness in the epigastric area and decreased bowel sounds are characteristic. 
Chronic pancreatitis is an inflammatory disease characterized by 
recurrentepisodes of abdominal pain that in certain individuals may result in 
progressive structural changes and permanent impairment of exocrine and 
endocrine functions
 (100)
. 
Carbohydrate intolerance: 
In children with chronic abdominal pain, increased flatulence and 
bloating, the diagnosis of carbohydrate intolerance should be considered. The 
breath hydrogen test following a lactose or fructose load will confirm the 
diagnosis. Exclusion of these offending agents may improve the symptoms. On 
the other hand, lactose intolerance has a very high prevalence in the general 
population and symptoms after a lactose load develop in only a few of the self-
reported milk-intolerant subjects 
(101)
. In a large sample of American patients, 
lactose malabsorption was found in 21–25% of IBS patients (102), a prevalence 
considered comparable to that in the general American population. Lebenthal et 
al 
(102)
 found a similar prevalence of lactase deficiency in children with 
recurrent abdominal pain and in children of a control group of similar ethnic 
background. Moreover, lactose free elimination diet resolved symptoms in a 
similar percentage of patients in the lactose absorbers and in the lactose 
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malabsorbers. As a result of the high independent prevalence of both conditions 
in the general population, the presence of chronic abdominal pain and lactose 
intolerance in one patient may be merely coincidental. Thus, the 
recommendation of an exclusion diet should be made with reasonable 
expectations, as it may be helpful in the resolution of symptoms in only a 
limited number of patients. 
Inflammatory bowel disease: 
Occult IBD was found in 1% of adult patients
(103)
and in 3–4% of 
pediatric patients
(104)
 evaluated for IBS. Some patients may complain for 
months or years of vague abdominal pain and intermittent diarrhea before 
being diagnosed as having IBD. The presentation of the abdominal pain is 
variable, depending on the site of bowel involvement. Terminal ileum and 
cecal disease in the setting of Crohn‟s disease is often associated with right 
lower quadrant discomfort and tenderness. Diagnosis is frequently delayed, 
with an average lag in diagnosis of approximately 7 months 
(105)
. A decrease in 
growth preceded the onset of any symptoms by at least 1 year in 24 of 50 
patients with Crohn‟s disease (106). 
Chronic constipation: 
IBS with constipation predominance and chronic constipation present 
many descriptive similarities 
(107)
. However, constipation in combination with 
abdominal pain has a wide differential diagnosis and constipation should not be 
judged as causing abdominal pain without consideration of alternative 
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diagnoses. In chronic constipation physical examination may reveal a fecal 
mass in the left lower quadrant and suprapubic region. Examination of the 
perineum should include assessment of the lower back, sacrum and site of the 
anus. Anal examination may reveal the presence of a fissure or a sentinel skin 
tag indicative of a fissure. Rectal examination may reveal the presence of a 
dilated rectum containing a hard fecalmass. A flat plate radiograph may help in 
the diagnosis in cases where obesityprecludes an appropriate abdominal 
examination. 
Gallstones: 
 Cholelithiasis is considered uncommon in infancy, childhood and 
adolescence, with a prevalence ranging from 0.2 to 0.5% 
(108)
. In older children, 
obesity, ileal disease and a family history of childhood gallstones have been 
associated with cholelithiasis
(109)
. Children with gallstones may have colicky or 
unspecific pain or remain asymptomatic. The pain is mostly located in the right 
upper quadrant or in the epigastrium, and may radiate to the back or right 
shoulder. Nausea and vomiting are present in more than 50% of cases. Fatty 
food intolerance is not commonly reported in children. Other biliary tree 
pathologies such as choledochalcyst may present with abdominal pain. 
Presentation is age dependent, with jaundice prevailing in children and 
abdominal pain in adults 
(110)
. 
Parasitic infections: 
 Positive fecal ova and parasite tests were found in only 2% of adult 
patients with IBS
(103)
.Giardia lamblia, Dientamoebafragilis, Cryptosporidium 
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and Blastocystishominismay be found in patients presenting with abdominal 
pain, often accompanied by anorexia, abdominal distension and diarrhea. 
Blastocystishominisis most likely to be non-pathogenic in the 
immunocompetent human host 
(111)
. 
Small-bowel bacterial overgrowth: 
 Symptoms of IBS may overlap with those of small-intestinal bacterial 
overgrowth (SBBO). Pimentel et al 
(112)
, in a prospective study, showed that 
78% of IBS patients had SBBO diagnosed by a lactulose hydrogen breathe test, 
and that the eradication of the overgrowth improved diarrhea and abdominal 
pain. A study of IBS patients with SBBO demonstrated significant motility 
abnormalities
 (113)
, leading the authors to conclude that dysmotilitywas the 
pathogenic mechanism linking SBBO to IBS. Another controlled study looking 
at the effects of antibiotics on IBS patients with alterations of the duodenal and 
colonic flora has also shown a significant improvement of symptoms in the 
group of patients receiving antibiotics 
(114)
. 
Celiac disease: 
 Patients with celiac disease may present with symptoms mimicking 
other conditions 
(115)
. A recent study has shown that celiac disease patients were 
initially diagnosed as having IBS in 37% of cases 
(116)
. In this study, only 32% 
of adults with celiac disease were underweight, and only 50% reported frequent 
diarrhea and weight loss. Anemia was present in 67% of the cases. Patients 
frequently presented with abdominal pain and bloating or gas which are 
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common clinical manifestations of functional bowel disorder. The Dutch 
College of General Practitioners states that celiac disease should be added to 
the differential diagnosis of IBS 
(117)
. A Canadian study revealed that, prior to 
being diagnosed as celiac disease, 37% of respondents consulted four or more 
family doctors 
(118)
. An Israeli study in 270 consecutive patientswhounderwent 
endoscopy for abdominal pain demonstratedceliacdisease in one out of 23 of 
the patients 
(119)
. 
Genitourinary disorders: 
 Pyelonephritis and obstructive conditions such as ureteral or 
pelviureteric junction obstruction may present with recurrent cramping 
abdominal pain, despite normal physical examination and urinalysis 
(120)
.Hematuria can be present in the setting of urinary tract infections, abuse, 
trauma, Henoch– Schönleinpurpura, or renal stones. Dysuria associated with 
abdominal pain can represent a sign of pyelonephritis, abuse, trauma, or a 
sexually transmitted disease
(121)
. In adolescent girls, a history of mid lower 
abdominal pain was found to have low sensitivity but high specificity for 
gynecological diseases 
(122)
.Gynecological pathology such as ovarian cysts, 
congenital uterine abnormalities and endometriosis should also be considered 
in the differential diagnosis of abdominal pain. Hematocolpos
(123)
 due to 
imperforate hymen may present with periodic lower abdominal pain and 
urinary retention. Endometriosis may begin 3–4 years after menarche. 
Clinically it may manifest as cyclic abdominal pain, nausea, vomiting, 
constipation or diarrhea 
(124)
.  
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Congenital anomalies: 
 Malrotation presents usually early in life, with 85% of all cases of 
midgut volvulus occurring in the first year. In neonates, symptoms are usually 
dramatic with sudden onset of bilious vomiting and a visibly seriously ill 
patient. Older infantsmay present with episodes of colicky abdominalpain. In 
one series, 20% of cases of malrotation in patients over 1 year of age presented 
with chronic abdominal pain 
(125)
. These patients often have vague, long-
standing abdominal complaints with or without emesis. The pain is often 
postprandial and may be accompanied by bilious emesis and diarrhea or 
evidence of malabsorption or proteinlosingenteropathy associated with 
bacterial overgrowth. Duplications of the alimentary tract are uncommon 
congenital abnormalities. The clinical presentations may be vague and diverse, 
depending on the location of the duplication 
(126)
. Presenting signs and 
symptoms include abdominal mass, vomiting, decreased oral intake, 
gastrointestinal bleeding, periumbilical tenderness and abdominal distension. 
Musculoskeletal pain: 
 Pain related to trauma is usually well localized and sharp in nature, and 
may be exacerbated by movement. Patients usually are able to recall a history 
of trauma or strain, but occasionally that history cannot be elicited. The 
diagnosis of costochondritis should be considered in adolescent patients 
complaining of chest or upper abdominal pain. Costochondritispain originates 
in the anterior chest wall, from where it may radiate into the chest, back, or 
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abdomen. Pain is reproducible by palpating the affected costal cartilage
(127)
. 
Diagnostic testing: 
 In patients with no alarm symptoms, the Rome criteria have a positive 
predictive value of approximately 98%, with additional diagnostic tests 
providing a yield of 2% or less 
(128)
. When needed, the exclusion of an organic 
condition can be accomplished by utilizing inexpensive, non-invasive and 
easily available diagnostic tests such as complete blood cell count, erythrocyte 
sedimentation rate, chemistry panel, liver and thyroid function studies, urine 
analysis and stool examination for blood, ova and parasites. Need for other 
diagnostic tests should be based on history and physical examination findings. 
The physician should avoid the lure of having to „rule out‟ an organic disease at 
all cost. Performing multiple tests may provide results that often are unrelated 
to the presenting symptom or have no clinical relevance (such as a mildly 
elevated sedimentation rate). Repeating tests to confirm the serendipitous 
findings may further increase anxiety and undermine the clinical diagnosis of 
functional bowel disorder. One could use time as the physician‟s ally, assuring 
the patient that no test is necessary at this point but if further symptoms present 
or the current symptom worsens the physician will not hesitate to proceed with 
further work-up. 
Blood and stool studies: 
 Hamm et al 
(103)
 studied 1452 patients with an established diagnosis of 
IBS and found that screening tests showed a low incidence of thyroid 
dysfunction, ova and parasite infestation, or colonic pathology. The authors 
44 
 
concluded that limited detection rates, added costs and the inconvenienceof 
these tests made the routine use of endoscopy,radiography, thyroid function 
tests, fecal ova and parasite determination and the lactulose hydrogen breath 
test questionable in the diagnostic evaluation of established IBS patients. In 
accordance with these results, Tolliver et al 
(129)
 performed fecal ova and 
parasite determinations in 196 patients with a possible diagnosis of IBS, and 
found no evidence of infection in any of them. In the same study, complete 
blood cell count, sedimentation rate, serum chemistries, thyroid profile and 
urinalysis were normal or yielded no useful clinical information. 
 A study designed to investigate the prevalence of elevated 
antiendomysial antibody titers in children with recurrent abdominal pain 
compared with healthy children found no association between abdominal pain 
and celiac disease 
(130)
. The study showed that 1% of patients in each group had 
positive celiac disease antibodies. An adult investigation studied serum 
antibody testing for celiac disease in patients with IBS symptoms and a control 
group, followed by upper endoscopy in positive cases. The study revealed that 
4.6% of patients in the group with possible IBS had positive antibodies in 
comparison with 0.67% in the control group, suggesting that testing for celiac 
disease may be one of the few cost-effective evaluations in patients with IBS 
(131)
. 
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Endoscopic studies: 
 A study investigating the presence of gastroesophageal reflux in children 
with recurrent abdominal pain concluded that pathological gastroesophageal 
reflux is a frequent finding in such children 
(132)
. Treatment of gastroesophageal 
reflux in this group of patients resulted inresolution or improvement of 
abdominal pain in71% of cases.Another study evaluating findings on 
endoscopic examinations in 62 Indonesian children with recurrent abdominal 
pain revealed pathological abnormalities including esophagitis, erosions and 
duodenitis in 50% of the patients
(133)
. In the absence of peptic ulcers, it is 
unclear how much these pathological findings contribute to the patients‟ 
symptoms. Endoscopy and biopsy performed in children evaluated for 
dyspepsia demonstrated that most children did not have significant mucosal 
disease. Inflammation without evidence of peptic ulceration was found in 38% 
of the patients with H. pylori being identified in only five cases (134). Follow-
up at 6 months to 2 years revealed that most subjects improved, regardless of 
the cause of dyspepsia. 
Ultrasound: 
 The diagnostic yield of a sonographic examination of the abdomen in 
children presenting with functional bowel disorders seems to be extremely low. 
Yip et al, in a retrospective evaluation of 644 ultrasound studies performed in 
children with the diagnosis of recurrent abdominal pain found abnormalities in 
only ten children, concluding that only children who have abdominal pain with 
atypical clinical features should receive sonographic screening 
(135)
. In another 
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study, the evaluation of 57 patients with chronic abdominal pain by abdominal 
and/or pelvic sonography revealed only one case of ovarian cyst that later 
resolved spontaneously
(136)
. Stordal et al
 (137)
 studied 44 children with recurrent 
abdominal pain without finding any abnormalities on ultrasound that could be 
related to the symptoms. 
Intraesophageal pH monitoring:  
 The diagnostic yield of esophageal pH monitoring in children presenting 
with chronic abdominal pain is controversial. A study of 44 children 
presenting with recurrent abdominal paindemonstrated gastroesophageal reflux 
in 25% of cases 
(137)
.No studies have compared outcomes between children 
who had pH monitoring studies and those who did not. The inconvenience 
associated with this test and itscost preclude its use at least in the initial 
evaluation of chronic abdominal pain. 
Lactose hydrogen breathe test: 
 This test is often used to diagnose lactose intolerance in patients with 
functional bowel disorders, but the cause–effect relationship between lactose 
intolerance and symptoms has been questioned 
(102)
. Lactose intolerance is 
discussed in more detail in a previous section of this chapter. 
Treatment: 
 There is no uniformly successful treatment or cure for functional bowel 
disorders. Once the diagnosis has been made, it is essential to emphasize the 
benign aspects of the history, physical examination and laboratory tests in order 
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effectively to reassure the patient and the family of their significance. Initial 
treatment of functional pain is based on reassurance and establishing an 
effective physician–patient–family relationship. Alleviatingsymptoms is one of 
the main goals of caring forpatients with functional bowel disorders, but a 
rational management of these disorders is often challenging, owing to the lack 
of objective diagnostic criteria and unclear pathogenesis. As a consequence, 
there are no specific, universally effective therapies 
(138)
. 
Reassurance:  
 It is of great importance to assure the family and the patient that the 
physician believes that the symptoms are „real‟ and that an organic or 
progressive disease is not present. An extensive explanation of the nature of the 
disorder should be given, discussing the problem as a common diagnosis and 
not just an exclusion of an organic disease. A comprehensive but easily 
understandable description of the nature of this group of disorders should be 
attempted. Comparisons with other common and benign entities such as 
headaches or muscle cramps may help. The family and the patient should be 
encouraged to ask questions and share their concerns, which should be 
addressed in depth to avoid fears and misconceptions. The main goal of the 
therapy is to re-establish a normal daily life for the patient and the family. The 
family should be discouraged from reinforcing the symptoms by allowing the 
child to miss school and leisure activities. Patients with perceived low self-
worth and academic competence may find the relief of responsibility asa 
benefit of the pain experience 
(139)
 meanwhile, patients with adequate 
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perception of their self-worth may find it discouraging. Fordyce and others 
have suggested that positive attention from others may serve as a secondary 
gain, transforming the painful experience into a rewarded activity that in turn 
couldreinforce symptoms, leading to further disability 
(140, 141)
. However, 
negative attention to pain in children with low self-esteem has been associated 
with increased pain behavior, possibly by creating affective distress that may 
further contribute to somatic symptoms
(139)
. Thus, the parents‟ attitude towards 
the pain experience should be balanced, showing support and understanding, 
but being aware that excessive attention to the painful experience and missing 
activities may allow some patients (especially those with low self-worth) to 
develop a sick role, perpetuating the symptoms. Behavior alternative to 
assuming the sick role should be encouraged and rewarded. Patients should be 
encouraged to discuss perceived triggering factors. Psychosocial stressors at 
home or school should be addressed. At school, strict toilet times or issues 
relating to social embarrassment to attend the restrooms should be discussed. It 
is often useful to communicate with the school nurse or teacher inorder to 
address these issues. Owing to the high index of symptomatic success with 
reassurance, medications are not necessary for every patient with functional 
abdominal pain. Drug therapy should be recommended only for patients with 
symptoms interfering with satisfactory quality of life. 
 
 
 
49 
 
Diet:  
 A detailed dietary history may identify factors that patients may feel as 
aggravating or provoking the symptoms. Food intolerance was perceived as a 
problem by 20% in an unselected UK population who responded to a 
questionnaire, but with controlled challenge the prevalence was slightly higher 
than 1%
(142)
. Food-induced symptoms are common reports among IBS patients, 
with 20–65% attributing their symptoms to adverse food reactions (143, 144). In a 
study of 200 IBS patients
(143)
, the effect of an exclusion diet was evaluated, 
with a symptomatic improvement in almost 50% of patients, indicating that a 
significant proportion of IBS patients could benefit from therapeutic dietary 
manipulation. However, such intervention is still controversial because the 
observed response rate replicates the average placebo response rate in IBS 
trials 
(73)
. Within IBS patients the subgroup of patients with diarrhea-
predominant symptoms seems to benefit the most by a trial of exclusion diet. 
Among those with abdominal pain with or without diarrhea, lactose, or 
excessive fructose or sorbitol intake may induce symptoms. The avoidance of 
gas- forming foods such as legumes, complex carbohydrates, lactose and 
fructose may provide symptomatic relief in some patients. High-fiber diets 
have long been used in adult IBS patients but the data in children are still 
preliminary and accomplishing a substantial increase in fiber consumption may 
be difficult 
(145, 146)
. As fibers decrease the whole-gut transit time, fiber-enriched 
diets may be more useful in the subgroup of patients with constipation 
(147, 148)
. 
Fiber may also decrease intraluminal pressures, reducing walltension and pain 
50 
 
(149)
. In committed familieswishing to increase dietary fibers, the change should 
be attempted gradually, as the excess of undigested carbohydrates in the colon 
results in fermentation with consequent increase of gas, aggravating IBS 
symptoms
(150)
. 
Laxatives:  
Patients with severe constipation may find relief by combining fiber with a 
laxative. It is our preference to use polyethylene glycol or a senna derivative, 
but other laxatives may be used according to the practitioner‟s preference. 
Lactulose should be avoided, as the increase of gas production derived from its 
use may trigger pain. 
Anticholinergic and antidiarrheal medications: 
 Some patients with diarrhea seem to benefit from an antidiarrheal 
preparation such as loperamide or diphenoxylate. Studies in adults6 and 
anecdotal experience seem to demonstrate that some patients find relief by 
using anticholinergics such as hyoscyamine
(151)
,dicyclomine or others that may 
modify intestinal tone and motility. These agents are best used on a sporadic 
basis, whenever the symptoms are present much like analgesics are used for 
headaches. When giving medications for pain, the high placebo response rate 
should be considered, as several preparations may work in the short term, only 
to relapse after a variable period of time 
(152)
.  
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Tricyclic antidepressants: 
 An additional option for treating chronic abdominal pain is the use of 
tricyclic antidepressants (TCA). TCA are used at smaller doses (0.2–0.4 mg/kg 
per day, 5–50mg/day) than needed for treatment of clinical depression. The 
analgesic effects of TCA and other antidepressants are independent of their 
effects on depression, and this information should be shared with the family 
and the patient. The beneficial effect of the TCA starts 3–7 days after the 
beginning of the treatment, while it takes 2–3 weeks for the onset of the 
antidepressant effects
(153)
. Relief of chronic pain with the use of antidepressants 
has been documented in the absence of any measurable antidepressantresponse, 
both in depressed patients 
(154)
 and in patients without clinical depression. In 
addition to its action on noradrenergic and serotoninergic receptors, the TCA 
have antimuscarinic and antihistaminic effects. Thus, these agents are 
especially effective in diarrhea-predominant patients 
(155)
 and those with 
disturbed sleep, when slowing intestinal transit and the side-effects of 
sleepiness may be of therapeutic value. The 
medication is best administered at bedtime. Other side-effects such as 
undesirable weight gain and the possibility of cardiac arrhythmias, although 
rare at such low doses, demand caution when prescribing these drugs. 
Electrocardiogram (EKG) monitoring can be performed at the practitioner‟s 
discretion. Amitriptyline, although probably more effective, has greater 
sedative and anticholinergic effects than imipramine 
(156)
. It is recommended 
that the medication be started at low doses, increasing the dose progressively as 
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needed to achieve a full dose in weeks 
(157)
. Other antidepressant drugs, such as 
selective serotonin reuptake inhibitors (SSRIs) are also being used in the relief 
of chronic pain 
(158)
.  
Selective serotonin re-uptake inhibitors: 
 SSRIs, such as paroxetine, fluoxetine, or sertraline, also seem to have 
therapeutic value in relieving symptoms in adult patients with functional bowel 
disorders
(151)
. SSRIs have become the most frequently prescribed 
antidepressant medications, owing to their favorable side-effect profile 
(159)
. 
Despite the growing popularity of SSRIs, there are few controlled studies of 
their efficacy in managing chronic pain syndromes. The effects of TCAsand 
SSRIs in the GI tract are different, with the TCAs slowing intestinal transit and 
SSRIs increasing motility in the small intestine 
(72, 160)
. Thus, a patient in whom 
the main symptom is constipation may benefit most from an initial trial of an 
SSRI, whereas a patient with increased bowel frequency may benefit from an 
antidepressant with anticholinergic properties. Recent reviews concluded that, 
although SSRIs may be effective, in most circumstances TCAs should remain 
the first-line antidepressant agents for chronic pain 
(154)
. 
Serotonin receptor antagonists: 
 There has been much recent interest in clinical gastrointestinal 
pharmacology focused on 5-HT3 and 5-HT4 receptors. Such receptors have 
beenshown to be involved in diverse sensory and motor regulatory processes in 
the GI tract. The 5-HT3 receptor has a role in modulating colonic motility and 
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visceral pain, increasing the threshold for sensation and discomfort, slowing 
colonic transit and improving stool consistency 
(161)
. A number of selective 5-
HT3 antagonists have been developed including ondansetron, granisetron, 
tropisetronrenzapride andzacopride. Ondansetron was the first 5-HT3 to be 
evaluated for its effects on the gut. It demonstrated some benefits in diarrhea-
predominant IBS, but no improvement in abdominal pain. Similarly, no 
reduction in pain was seen with granisetron. This modest efficacy led to the 
search for a 5-HT3 with greater potency. Alosetron, a newer 5-HT3 receptor 
antagonist, has greater potency than ondansetron, and good bioavailability 
(162)
. 
Treatment with alosetron has led to significant relief of abdominal pain and 
discomfort in women with diarrhea-predominant IBS. Though generally safe, 
its use has been associated with severe constipation and ischemic colitis. It is 
currently available in the USA as part of a limited access program. 5-HT4 
agonists such as tegaserod and prucalopride, have been developed for patients 
with IBS and constipation. Tegaserod has demonstrated efficacy in the short-
term relief of abdominal pain and discomfort in adult women with 
constipationpredominant IBS
(163)
 and is commercially available for this 
indication. Adverse events, particularly loose stools, are compatible with an 
exaggerated pharmacological response to tegaserod and are most common 
during the first 2 days of therapy. 
Alternative and complementary therapy: 
 Despite the interventions described above, some patients will continue 
to experience symptoms, suggesting that current treatments that target the 
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predominant symptom are only partially effective, presumably because they do 
not resolve the underlying cause of functional bowel disorder 
(73)
. The large 
number of patients in whom these therapies fail has prompted an interest in 
alternative therapies such as diet supplements, probiotics and ancient 
therapeutic modalities such as Chinese medicine. Peppermint oil 
(Menthapiperita), which is commonly found in many over-the-counter 
preparations for IBS, has long been recognized as a spasmolytic agent that 
relaxes GI smooth muscle, relieving pain. Placebo-controlled studies have 
shown an overall improvement in IBS patients who used peppermint oil 
(164, 
165)
. A double-blind clinical trial in Chinese medicine demonstrated that herbal 
therapy was effective in the management of symptoms related to IBS 
(166)
. 
Natural and 228 Functional abdominal pain and other functional bowel 
disorders herbal medications are not without adverse effects and patients 
should not take these products without medical supervision. A variety of other 
herbal preparations have been studied with different methodologies, resulting 
in mixed results. More well-designed, controlled trials must be performed to 
identify other complementary therapies, with validation of the safety and 
efficacy of their use 
(95)
. Another alternative therapeutic strategy for patients 
with significant pain is to use hypnotherapy or psychotherapy
(167-169)
. 
Hypnotherapy has been shown to be effective in the treatment notonly of 
gastrointestinal symptoms but also ofurological, sexual and psychological 
symptoms that are often associated features of IBS in adults 
(170)
. Effective 
psychological treatments include cognitive–behavioral interventions, dynamic 
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or interpersonal psychotherapy and stress management. In a review of 
published psychological trials, Talley et al found methodological problems in 
all the studies, concluding that the efficacy of psychological treatment for IBS 
could not yet be established 
(171)
.Despite the fact that alterations of enteric flora 
may play a role in IBS, convincing evidence for a pathogenic role of bacterial 
overgrowth or for a beneficial effect of probiotic therapy is still scant. A review 
of the therapeutic role of probiotics concluded that further studies are needed to 
identify particular subgroups of patients with IBS who could benefit from their 
use 
(172)
. More recently, however, a very encouraging randomized, doubleblind 
and placebo-controlled study in adults with diarrhea-predominant IBS showed 
efficacy for the probiotic preparation „VSL3‟ (173). These findings will of course 
have to be reproduced in children. In chronic cases of refractory pain, referral 
to specialized treatment centers for an interdisciplinary pain management 
approach may be the most efficient method of treating disability. Natural 
history Functional abdominal pain is not always a benign condition with a 
satisfactory outcome. Long-term psychiatric disorders have been identified in 
patients suffering from functional abdominal pain in childhood
(174)
. Children 
with abdominal pain do not necessarily continue to experience physical 
symptoms in adulthood but may have an increased risk of adult psychiatric 
disorders 
(175)
. 
Future trends: 
The key to revealing the mechanisms and improving therapy of functional 
bowel disorders lies in the collaborative efforts among basic scientists, clinical 
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investigators, physicians and behaviorists. Progress in better understanding of 
the sensory mediators and the causes of visceral afferent dysfunction should 
lead to treatments that reduce the visceral perception or reflex motor responses 
that lead to symptoms. We should continue to pursue investigations looking for 
biological markers of this group of disorders. Education of patients and 
physicians on the nature and therapy of this group of conditions, in conjunction 
with early identification of psychosocial variables and development of better 
therapies, are fundamental strategies in order to reduce patient suffering and the 
elevated costs to society associated with functional bowel disorders 
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RESULTS 
 Children who attended the PediatricsOPD for abdominal pain were 
given a questionnaire developed from Rome III Diagnostic Questionnaire for 
the Pediatric Functional GI Disorders. Parents filled up the questionnaire and 
children who fulfilled the ROME III criteria for chronic abdominal pain (i.e. 
abdominal pain more than 2 months) were explained about the study. Saps et al 
and Tilburg et alprovide for validation of ROME III questionnaire 
(184, 185)
. 
After obtaining informed consent children were then included in the study. 
Total of 66 children were included in this study, of them cases were 31 and 
controls were 35. Ultrasound gallbladder measurements were done for the 
study population with 6 hours of fasting and 30 minutes following standard 
meal containing 30 gram of fat. Children were age and gender matched.  
I. Base line characteristics of cases and controls 
  There were total of 66 children included in this study. The mean age of 
cases and controls were 10.14 ± 2.71 years and 11.54 ± 1.94 years respectively 
(Table 1). The mean age of boys and girls in the cases group were 10.4 ± 2.73 
years (ranging from 6.5 to 15 years) and 10.1 ± 2.71 years (ranging from 5 to 
15 years) respectively. The mean age of boys and girls in the controls group are 
11.6 ± 1.92 years (ranging from 5 to 15 years) and 12.2 ± 1.61 years (ranging 
from 7 to 14 years). The mean height of the cases group was 132.9 ± 15.9 
(ranging from 100 to 165cms) and that of controls was 145.14 ± 11.6 (ranging 
from 110 to 159cms). The mean weight of cases and controls were 27.3 ± 10.5 
and 33.8 ± 6.6 respectively. The mean body mass index (BMI) was 14.9 ± 2.8 
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kg/m
2 
(range of 11.3 to 26.3 kg/m
2
) in case group and 15.9 ± 1.8 kg/m
2
 (range 
from 11.9 to 19.5 kg/m
2
) in the control group (Fig 6). Out of 31 cases there 
were 11 boys (35.5%) and 20 (64.5%) girls respectively. And in 35 controls 
there were 23 (65.7%) boys and 12 (34.3%) girls respectively. So a total of 34 
boys and 32 girls were included in this study. 
II. Symptoms associated in children with chronic abdominal pain  
  The following symptoms were reported by 31 children in the case 
group: abdominal pain (n=31), upper abdominal pain (n=11), lower or 
periumbilical abdominal pain (n=20), relieving of abdominal pain following 
defecation (n=7), change in pain with frequency of passing stool (n=1), change 
in pain with form of stool (n=2), 2 or more episodes in last year lasting more 
than 1 hour or longer and restricting daily activities (n=5), symptom free period 
between pain (n=30), any associated symptoms like no appetite, nausea, 
vomiting, pale skin, headache, eyes sensitive to light, headache, difficulty in 
sleeping, pain in arms, legs, or back, fainting or dizziness (n=10) and misses 
activities once in a while (n=10) (Table 2). In the case group 77.4% continued 
to have abdominal pain even after defecation.In cases almost 26 (83.9%) did 
not have any restriction of activities due to abdominal pain. in cases 96.8% of 
them had symptom free period between abdominal pain episodes. 
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III. Comparison of pre-prandial and post-prandial gallbladder volumes 
in cases and controls 
 The mean pre-prandial gallbladder volumes of cases and controls were 
8.35 ± 3.97 (cm
3
) and 7.46 ± 3.04 (cm
3
) respectively (Fig 7). Though the pre-
prandial GB volume was visibly greater than the control group, yet there was 
no statistical significance (p value – 0.232) (Table 3). The mean post-prandial 
volumes of cases and controls were 3.52 ± 1.73 (cm
3
) and 2.83 ± 1.04 (cm
3
) 
respectively (Fig 8). Though the post-prandial GB volume was visibly greater 
than the control group, yet there was no statistical significance (p value – 
0.390) (Table 4). The baseline gallbladder volume changes in cases and 
controls, comparing their pre-prandial and post-prandial were 42% and 37%   
IV. Gallbladder ejection fraction in cases and controls 
  Ejection fraction is measured with the obtained GB pre-prandial and 
post-prandial GB volume. The mean ejection fraction of cases and controls 
were 51.72 ± 17.76% and 57.37 ± 23.26% respectively (Fig 9). But there was 
no statistical significance in ejection fraction of cases and controls (p value – 
0.158) (Table 5) 
V. Pain distribution and ejection fraction relation in cases 
 To identify the association, if exists, between upper abdominal pain and 
GB dysmotility, the ejection fraction of GB in children with upper abdominal 
pain was compared with ejection fraction of GB in children with lower 
abdominal pain.  Ejection fraction was compared with the site of abdominal 
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pain between upper abdominal pain and periumbilical/lower abdominal pain. 
This was done because in location to GB in right upper quadrant, so cases with 
upper abdominal are high likely to have less ejection fraction in cases group. 
The mean ejection fractions of cases with upper abdominal pain and 
periumbilical or lower abdominal pain were 41.7 ± 17.1% and 57.2 ± 15.9% 
respectively (Fig 10). This is statistically significant (p value – 0.000), it shows 
that children with upper abdominal pain had lesser GB contractility than in 
children with lower or periumbilical abdominal pain (Table 6). 
VI. Correlation with BMI and GB contractility 
 In order to identify any possible association between increasing BMI 
and GB contractility among cases and controls, a subgrouping of cases were 
done into 2 groups namely, BMI<15 and BMI ≥ 15. The mean ejection fraction 
of cases with BMI< 15 and ≥ 15 were 54.28 ± 17.99 % and 48.19 ± 17.53 % 
(Fig 11), it is statisticallysignificant (p value is 0.000) (Table 7). In cases 
children with BMI<15 had better ejection fraction than those with BMI ≥ 15. In 
Pearson‟s correlation method showed a weak negative correlation between 
BMI and gall bladder contractility in cases. The mean ejection fraction of 
controls with BMI< 15 and ≥ 15 were 39.18 ± 28.16 % and 63.68 ± 17.94 % 
(Fig 12), it is statistically significant (p value is 0.003) (Table 8). In the control 
group the mean ejection fraction was more in children with BMI ≥ 15. 
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VII. Correlation of cases and controls with gallbladder ejection fraction 
< 40% and BMI 
In the case group there were 8 children with gallbladder dysmotility (i.e. 
gallbladder ejection fraction less than 40%). Among the 8, 4 children had 
BMI < 15 and 4 children had BMI ≥ 15. And there were totally 9 children 
with gallbladder dysmotility in the control group. In them 5 children had 
BMI <15 and 4 of them had BMI≥ 15. In both cases and controls the 
children with gallbladder dysmotility (i.e. ejection fraction less than 40%) 
were compared with BMI of the study population by chi-square method and 
Pearson‟s correlation (Fig 13 and 14). On applying Chi-Square test, this 
observation was not statistically significant (p value – 0.103) (Table 9 and 
10) 
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Table 1: Baseline characteristics of study population 
 Cases Controls 
N 31 35 
Age ±SD (in years) 10.14 ± 2.71 11.54 ± 1.94 
Height ±SD (cm) 132.9 ± 15.9 145.14 ± 11.6 
Weight ±SD (kg) 27.3 ± 10.5 33.8 ± 6.6 
BMI ±SD (kg/m
2
) 14.9 ± 2.8 15.9 ± 1.8 
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Figure 6: Baseline characteristics of study population 
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Table 2: Cases presenting with various symptoms 
Symptoms Number of children in cases group 
Upper abdominal pain 11 
Lower or periumbilical abdominal 
pain 
20 
Decrease in abdominal pain after 
defecation 
7 
Change in pain with frequency of 
passing stool 
1 
Change in pain with form of stool 2 
2 or more episodes in last year 
lasting more than 1 hour or longer 
and restricting daily activities 
5 
Symptom free period between pain 30 
Associated symptoms like no 
appetite, nausea, vomiting, pale 
skin, headache, eyes sensitive to 
light, headache     difficulty in 
sleeping, pain in arms, legs, or 
back, fainting or dizziness 
10 
Misses activities once in a while 10 
 
 
 
 
 
 
65 
 
Table 3: Pre-prandial gallbladder volume in cases and controls 
 
Mean 
Pre-prandial gallbladder volume in cases (cm
3
) 8.35 ± 3.97  
Pre-prandial gallbladder volume in controls 
(cm
3
) 
7.46 ± 3.04  
P value (t test method) 0.232 
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Figure 7: Pre-prandial gallbladder volume in cases and controls 
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Table 4: Post-prandial gallbladder volume in cases and controls 
 
Mean 
Post-prandial GB volume in cases (cm
3
) 3.52 ± 1.73   
Post-prandial GB volume in controls (cm
3
) 2.83 ± 1.40   
P value (t test method) 0.390 
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Figure 8: Postprandial gallbladder volume in cases and controls 
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Table 5: Gallbladder ejection fraction in cases and controls 
 Mean 
Gallbladder ejection fraction in cases 
(%) 
51.72 ± 17.76 
Gallbladder ejection fraction in 
controls (%) 
57.37 ± 23.26 
P value (t test method) 0.158 
 
 
 
 
 
 
 
 
 
 
70 
 
Figure 9: Gallbladder ejection fraction in cases and controls 
 
 
 
48 50 52 54 56 58
Mean
51.72 %
57.37 %
Gallbladder ejection fraction in controls Gallbladder ejection fraction in cases
71 
 
Table 6: Ejection fraction in cases with upper abdominal pain and lower 
or periumbilical abdominal pain. 
 Mean ejection fraction 
Upper abdominal pain 41.7 ± 17.1% 
Lower or periumbilical abdominal pain 57.2 ± 15.9% 
P value (t test method) 0.000 
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Figure 10: Ejection fraction in cases with upper abdominal pain and lower 
or periumbilical abdominal pain. 
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Table 7: Correlation between BMI and ejection fraction in cases 
 Mean ejection fraction in Cases 
BMI < 15 54.28 ± 17.99 % 
BMI ≥ 15 48.19 ± 17.53 % 
P value (t test method) 0.000 
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Figure 11: Correlation between BMI and ejection fraction in cases 
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Table 8:Correlation between BMI and ejection fraction in controls 
 Mean ejection fraction in controls 
BMI < 15 39.18 ± 28.16 % 
BMI ≥ 15 63.68 ± 17.94 % 
P value (t test method) 0.003 
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Figure 12: Correlation between BMI and ejection fraction in controls 
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Table 9:Correlation between ejection fraction and BMI in cases 
BMI < 15 
Ejection fraction 
</= 40% 
Ejection fraction 
>40% 
Total 
BMI < 15 4 13 17 
BMI ≥ 15 4 10 14 
Total 8 23 31 
P value (chi-
square method) 
1.0000 
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Figure 13: Correlation between ejection fraction and BMI in cases 
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Table 10:Correlation between ejection fraction and BMI in controls 
 
Ejection fraction 
</= 40% 
Ejection fraction 
>40% 
Total 
BMI < 15 5 6 11 
BMI ≥ 15 4 20 24 
Total 9 26 35 
P value (chi-
square method) 
0.103 
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Figure 14: Correlation between ejection fraction and BMI in controls 
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DISCUSSION 
Chronic abdominal pain is one of the commonest gastrointestinal 
symptoms in children presenting to outpatient department
 (1)
.Campbell et al 
study on children with chronic abdominal pain undergoing laparoscopic 
cholecystectomy for biliary dyskinesia diagnosed by quantitative 
cholescintigraphy with CCK stimulation showed86% of children had chronic 
abdominal pain 
(187)
.In the present study 32.2% of the children missed their day 
today activities due to chronic abdominal pain.  
Though the exact prevalence of CAP in our country is not exactly 
known, studies from the western world have documented 13% among middle 
school children and 17% in high school children experiencing weekly 
abdominal pain. Over all about 2 to 4% of all pediatric outpatient visits are due 
to CAP in children. Extensive evaluation for CAP in children does not show 
any obvious organic reason for abdominal pain. Recent evidences show causal 
association between gallbladder dysmotility and CAP. 
 In the recent times USG has been used for evaluating gallbladder 
ejection fraction, because of its convenience in using and no radiation 
advantages. Mehra et al 
(183)
 has prospectively studied association between 
gallbladder dysmotility in children with chronic functional constipation, using 
USG. Hence in our present study USG was used to evaluate the gallbladder.  
In our study a total of 31 subjects presented with CAP, among which 
25.8 % of children had an ejection fraction < 40% following a fatty meal 
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suggesting gallbladder dysmotility. But a majority (74.2%) of children though 
had CAP by definition, had an ejection fraction > 40% suggesting that some 
unknown cause for abdominal painunrelated to gallbladder dysmotility. 
Interestingly a similar percent of healthy controls (Age and Sex matched) also 
had gallbladder dysmotility and was symptom free. Suggesting that gallbladder 
dysmotility may not be symptomatic in all children. 
The mean pre and post-prandial gallbladder volume of cases was 8.35 ± 
3.97 (cm
3
)2.83 ± 1.40 (cm
3
). The volume of gallbladder among cases was 
significantly higher than the healthy controls who had a mean pre and post-
prandial gallbladder volume of 3.52 ± 1.73 (cm
3
)7.46 ± 3.04 (cm
3
) 
respectively. A high mean pre-prandial gallbladder volume might suggested an 
underlying gallbladder dysmotility, though there was no significant change in 
the ejection fraction of gallbladder among cases and controls (51.72 ± 17.76 
versus  57.37 ± 23.26P value 0.158). 
In our study we sub grouped the cases based on the sight of abdominal 
pain as upper abdominal pain and lower or periumbilical abdominal pain. The 
mean ejection fraction among cases with upper abdominal pain was 41.7 ± 
17.1% were as cases with lower or periumbilical abdominal pain had higher 
ejection fraction 57.2 ± 15.9% and it is statistically significant                            
(Pvalue = 0.000). In the study by Michail et al (186), who looked into clinical 
features of children with biliary dyskinesia and underwent laparoscopic 
cholecystectomy, found that 93% of children presented with right upper 
quadrant pain. This observation is similar to results of our study were 36.3 % 
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with  upper abdominal  painhad gallbladder dysmotility  and only 15% of 
children with lower or periumbilical abdominal pain had gallbladder 
dysmotility. The mean ejection fraction among the entire population of children 
with upper abdominal pain was higher than the mean ejection fraction of 
children with lower or periumbilical abdominal pain(41.7 ± 17.1% versus 57.2 
± 15.9% P value = 0.000). So children with upper abdominal pain are likely to 
have an underlying gallbladder dysmotility. 
On comparing the effect of BMI of the individual on gallbladder 
dysmotility we have found that children with chronic abdominal pain with       
BMI < 15 had better ejection fraction when compared to children with chronic 
abdominal pain with BMI ≥15. This difference in mean ejection fraction among 
cases with BMI < 15 and ≥15 was statistically significant. Suggesting that 
children with chronic abdominal pain with low BMI had better gallbladder 
contractility. 
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CONCLUSION 
 Our study is the first of its type in evaluating causal association of 
gallbladder dysmotility in children with chronic abdominal pain 
 The ROME III questionnaire is a reliable tool to assess and classify 
chronic abdominal pain in children in an office setting 
 USG can be utilized in clinical practice for assessing gallbladder 
contractility 
 In our study among 31 children with chronic abdominal pain 25.8% had 
gallbladder dysmotility  
 The mean ejection fraction of children with chronic abdominal pain and 
gallbladder dysmotility was 30.2% 
 36.3% of children with upper abdominal pain had gallbladder 
dysmotility as compared to 15% of children with lower / periumbilical 
abdominal pain 
 A statistically significant difference in the mean ejection fraction of 
children with upper abdominal pain and lower / periumbilical pain was 
observed (41.7 ± 17.1% versus 57.2 ± 15.9% p value – 0.000) 
 The mean gallbladder volume among cases was higher than the healthy 
controls group but this difference was not statistically significant (3.52 ± 
1.73 (cm
3
) versus 2.83 ± 1.04 (cm
3
) p value – 0.390) 
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 On applying Pearson‟s correlation  for children with chronic abdominal 
pain and their BMI, there exists a negative correlation with increasing 
BMI (p value < 0.000) 
 25.7% of the controls also had an ejection fraction < 40% but were 
asymptomatic    
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LIMITATIONS 
 Small sample size 
 Bias due to inter observer variation in USG finding were few limitations 
of the present study 
 Further studies to confirm gallbladder dysmotility by using quantitative 
cholescintigraphy with CCK stimulation  might throw light on the 
reliability of USG to evaluate gallbladder dysmotility 
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Institutional Human Ethics Committee 
PSG Institute of Medical Sciences and Research, Coimbatore 
 
Assent to be in a Research Study 
For children between 7-18 years old 
 
Why are we meeting with you? 
 
We want to tell you about something we are doing called a research study.  A research 
study is when doctors collect a lot of information to learn more about something related 
to health and disease. Dr.Raaghul.Cand some other doctors are doing a study to learn 
more about gallbladder contractility. After we tell you about it, we will ask if you‘d like 
to be in this study or not. 
 
Why are we doing this study? 
 
We want to find out, whether gallbladder contractility has any association in children with 
chronic   abdominal pain 
So we are getting information from lots of boys and girls like you. 
In the whole study, there will be about 60 children. 
 
What will happen to you if you are in this study? 
 
Only if you agree, two things will happen: 
 
1. Your child will undergo ultrasound abdomen after 6 hours of fasting and 60min 
following a fatty meal 
 
2. You will need to answer some questions about your child‘s abdominal pain 
 
Will this study hurt? 
 
No this study doesn‘t hurt 
 
Will you get better if you are in this study? 
No, this study won‘t make you feel better or get well.  But the doctors might find out 
something that will help other children like you later. 
 
Will everybody come to know about my condition? (Confidentiality) 
We will not tell other people that you are in this research and we won't share information 
about    you to anyone who does not work in the research study 
 
 
 
Is this bad or dangerous for me? (Risks involved)  
No this test is not bad or dangerous 
 
 
 
Will you tell me the results? 
No the result will not be shared 
 Do you have any questions? 
You can ask questions any time.  You can ask now.  You can ask later.  You can talk to 
me or you can talk to someone else. 
 
Do you have to be in this study? 
No, you don‘t.  No one will be mad at you if you don‘t want to do this.  If you don‘t want 
to be in this study, just tell us.   Or if you do want to be in the study, tell us that.  And, 
remember, you can say yes now and change your mind later.  It‘s up to you. This will not 
affect in any way your future treatment in this hospital. 
 
 
Who can I talk to or ask questions to? 
List and give contact information for those people who the child can contact easily (a 
local person who can actually be contacted). Tell the child that they can also talk to 
anyone they want to about this (their own doctor, a family friend, a teacher). 
 
If you don’t want to be in this study, just tell us. If you want to be in this study, just tell us. 
This will not affect in any way your future treatment in this hospital. 
The doctor will give you a copy of this form to keep. 
 
 
SIGNATURE OF PERSON CONDUCTING ASSENT DISCUSSION 
I have explained the study to ______________________(print name of child here) in 
language he/she can understand, and the child has agreed to be in the study. 
 
 
__________________________________   _______________ 
Signature of Person Conducting Assent Discussion  Date 
 
_______________________________ 
Name of Person Conducting Assent Discussion (print) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part 2: Certificate of Assent 
 
I have read this information (or had the information read to me)  I have had my questions 
answered and know that I can ask questions later if I have them.  
 
I agree to take part in the research. 
 
OR 
I do not wish to take part in the research and I have not signed the assent 
below.___________ (initialed by child/minor) 
 
Only if child assents: 
Print name of child ___________________ 
Signature of child: ____________________ 
Date:________________ 
day/month/year 
 
 
If illiterate: 
A literate witness must sign. Participants who are illiterate should include their thumb 
print as well.   
 
I have witnessed the accurate reading of the assent form to the child, and the individual 
has had the opportunity to ask questions. I confirm that the individual has given consent 
freely.  
 
Name of witness (not a parent)_________________  AND    Thumb print of participant 
Signature of witness ______________________ 
Date ________________________ 
                Day/month/year 
  
 
 
 
 
 
I have accurately read or witnessed the accurate reading of the assent form to the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that the 
individual has given assent freely.  
 
Name of researcher: DR.RAAGHUL.C 
 
*Modified from the Informed Assent form template for children/minors –World Health 
organization 
  
 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
 
 
I DR.RAAGHUL.C, am carrying out a study on the topic: 
GALLBLADDER CONTRACTILITY IN CHILDREN WITH 
CHRONIC ABDOMINAL PAIN as part of my research project being 
carried out under the aegis of the Department of: 
PAEDIATRICSPSGIMSR 
 
My research guide is: DR.JOHNMATTHAIMBBSDCH MD PAED. 
GASTROENTROLOGIST (FELLOWSHIP) 
 
The justification for this study is: Chronic abdominal pain affects the 
quality of life in children and identifying gallbladder contractility 
association in these children by non-invasive technique will help in 
management of improving their quality of life 
The objectives of this study are:  
 
Primary Objective: To assess gallbladder contractility in children with 
chronic abdominal pain  
 
Secondary Objective: To assess the association between gallbladder 
contractility and severity, duration of abdominal pain and association of 
gastro intestinal complaints like dyspepsia, irritable bowel syndrome etc. 
 
 
Sample size: 60 
 
Study volunteers / participants are (specify population group & age 
group): children aged 5 to 15years with chronic abdominal pain 
 
Location: Department of PaediatricPSGIMSR Coimbatore 641004.  
 
We request you to kindly cooperate with us in this study. We propose 
collect background information and other relevant details related to this 
study. We will be carrying out: 
 
Questionnaire – 20minutes  
 
Radiological Examination: Ultrasound abdomen will be done after 
6hours of fasting. Following which child will be fed with fatty meal and 
repeat ultrasound abdomen at 60 minutes.    
 
No. of times it will be done:  Twice  
 
Whether ultrasound abdomen is part of routine procedure or for research 
(study) purpose:   
 
1. Routine procedure 2. Research purpose   
 
Specify purpose, discomfort likely to be felt and side effects: child may 
have some physical discomfort during examination. 
 
Data collected will be stored for a period of 5 years. We will not use the 
data as part of another study. 
 
 
Benefits from this study: The relation between gallbladder dysfunction 
and abdominal pain will be found  
 
Risks involved by participating in this study: nil 
 
How the results will be used: from the study gallbladder dysfunction and 
abdominal pain caused by it can be prevented by correcting gallbladder 
dysfunction 
 
If you are uncomfortable in answering any of our questions during the 
course of the interview / biological sample collection, you have the right 
to withdraw from the interview / study at anytime. You have the 
freedom to withdraw from the study at any point of time. Kindly be 
assured that your refusal to participate or withdrawal at any stage, if you 
so decide, will not result in any form of compromise or discrimination in 
the services offered nor would it attract any penalty. You will continue to 
have access to the regular services offered to a patient. You will NOT be 
paid any remuneration for the time you spend with us for this interview / 
study. The information provided by you will be kept in strict confidence. 
Under no circumstances shall we reveal the identity of the respondent or 
their families to anyone. The information that we collect shall be used for 
approved research purposes only. You will be informed about any 
significant new findings - including adverse events, if any, – whether 
directly related to you or to other participants of this study, developed 
during the course of this research which may relate to your willingness to 
continue participation. 
 
Consent: The above information regarding the study, has been read by 
me/ read to me, and has been explained to me by the investigator/s. 
Having understood the same, I hereby give my consent to them to 
interview me. I am affixing my signature / left thumb impression to 
indicate my consent and willingness to participate in this study (i.e., 
willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal 
Representative:  
 
 
Signature of the Interviewer with date:     
 Witness: 
 
Contact number of PI: 9952665177 
 
Contact number of Ethics Committee Office:  During Office hours: 0422 
2570170 Extn.: 5818  
                                                                        After Office hours: 
9865561463 
SOP 03-V 3.0 / ANX10-V 3.0 
 
Institutional Human Ethics Committee 
PSG Institute of Medical Sciences and Research, Coimbatore 
 
Parental Consent Form 
 
Title of Study: Gallbladder contractility in children with chronic abdominal pain 
 
Name of the Principal Investigator:Dr.Raaghul.C 
 
Department:  
 
Your (son/daughter/child/infant/adolescent youth) is invited to participate in a study of 
(describe the study).  
 
My name is Dr.Raaghul.Cand I am a junior resident at PSG Institute of Medical Sciences 
and Research, Coimbatore. This study is (state how study relates to your program of work or 
your supervisor‘s program of work).  
 
I am asking for permission to include your (son/daughter/child/infant/adolescent youth) in this 
study because  
  
I expect to have 60 (Number) participants in the study. 
If you allow your child to participate, (state who will actually conduct the research) will 
(describe the procedures to be followed.) 
 
Any information that is obtained in connection with this study and that can be identified with 
your (son/daughter/child/infant/adolescent youth) will remain confidential and will be 
disclosed only with your permission. His or her responses will not be linked to his or her 
name or your name in any written or verbal report of this research project. 
 
Your decision to allow your (son/daughter/child/infant/adolescent youth) to participate will 
not affect your or his or her present or future relationship with PSGIMS&R or PSGHospitals  
or (include the name of any other institution connected with this project). If you have any 
questions about the study, please ask me. If you have any questions later, call me at 
09952665177. If you have any questions or concerns about your 
(son/daughter/child/infant/adolescent youth)‘s participation in this study, 
call………………………………….. 
 
You may keep a copy of this consent form. 
You are making a decision about allowing your (son/daughter/child/infant/adolescent youth) 
to participate in this study. Your signature below indicates that you have read the information 
provided above and have decided to allow him or her to participate in the study. If you later 
decide that you wish to withdraw your permission for your 
(son/daughter/child/infant/adolescent youth) to participate in the study, simply tell me. 
 
You may discontinue his or her participation at any time. This will not affect in any way 
your future treatment in this hospital. 
 
Printed Name of (son/daughter/child/infant/adolescent youth) 
 
 
Signature of Parent(s) or Legal Guardian with Date  Signature of Investigator 
with Date 
   
  
 
 
 
PROFORMA 
 
Name:                                                   Age:                  Sex: 
IP number:                                           OP number: 
1. History of any abdominal surgery           (YES)/ (NO) 
If yes then specify ……………………………………………….. 
2. Previously diagnosed chronic abdominal pathology     (YES)/(NO) 
If yes then specify………………………………………………… 
3. Does your child have upper abdominal pain or discomfort 
―Several times a week‖ or more often                                                                                                                                                                                                                                                                                                                                                                                             
(YES) / (NO) 
 
4. Is the duration of upper abdominal pain or discomfort is ―2 months‖ or 
longer    (YES)/(NO) 
 
5. Pain exclusively relieved with defecation (―sometimes‖ or less often)                       
(YES)/(NO) 
 
6. Periumbilical/lower abdominal pain/discomfort ―once a week‖ or more 
often               (YES)/(NO) 
 
7. Duration of Periumbilical/lower abdominal pain/discomfort is ―2 
months‖ or longer   (YES)/(NO) 
 
8. Pain associated with change in bowel movement form: softer or harder 
               (YES)/(NO) 
 
9. Pain associated with change in bowel movement frequency:  more or  
fewer                (YES)/(NO) 
 
10. In the past year, 2 or more episodes of severe pain lasting 1 hour or 
longer and causing restriction in daily activities     
             (YES)/(NO) 
 
11. Two or more of the following in past 2 years when child has abdominal 
pain 
a. No appetite        b. Nausea               c. Vomiting 
d. Pale skin            e. Headache           f. Eyes sensitive to light 
 
12. Symptom-free periods between pain episodes                                                                 
(YES)/(NO) 
 
13. EITHER Two or more other somatic symptoms ―once a week‖ or more 
often 
 
A. Headache                              B. Difficulty sleeping 
C. Pain in arms, legs, or back    D. Faint or dizzy 
OR 
14. Misses activities ―once in a while‖ or more often   
                     (YES)/(NO) 
 
 
Gallbladder Contractility Data Collection Form 
 
 
Name:Age:Sex: 
IP No:                                                       OP No: 
 
During ultrasound, the greatest length (L), greatest transverse width (W), 
and greatest anteroposterior diameter (A) of the gallbladder were 
measured. The series gallbladder volumes were calculated by the 
following Dodd‘s Formula 
 
Gallbladder Volume (V) = 0.52 x L x W x A 
 
Where VO = gallbladder volume before the test meal, 
Vn = gallbladder volumes 30min after the test meal 
Gallbladder EF (Ejection Fraction) (%) = [(Vo – Vn) / Vo] x 100% 
 
 
 
 
 Fasting 
State 
Post Prandial  
(60min after fatty meal) 
Greatest length L   
Greatest transverse width W   
Greatest anteroposterior diameter 
A 
  
Volume VO = Vn =  
ROME III CRITERIA FOR FUNCTIONAL GASTRO 
INTESTINAL DISORDER IN CHILDREN 
  
LIST OF ABBREVIATIONS 
 
RAP   –  Recurrent Abdominal Pain  
CCK   –  Cholecystokinin  
VIP   –  Vasoactive Intestinal Peptide  
GB  -  Gallbladder 
USG   –  Ultrasonography 
IBS   –  Irritable Bowel Syndrome 
SO   -  Sphincter of Oddi 
ENS  –  Enteric Nervous System 
CNS   –  Central Nervous System   
TCA  -  Tricyclic Antidepressants 
SSRIs -  Selective Serotonin Reuptake Inhibitors 
 
Sl.No. AGE Sex ABDSUR CHABDPATH ABDP UPABDP UMABDP DUR RELDEF CHANGEFREQ CHANGPAIN >2EPI NOSYM ACTMISS FGBVOL PPGBVOL EF
1 5 .5 2 2 2 1 2 1 1 2 2 2 1 1 1 6.58 2.9 55
2 10 1 2 2 1 1 2 1 2 2 2 2 1 2 3.5 2.5 28
3 13 2 2 2 1 1 2 1 2 1 1 2 1 1 5.1 2.74 46
4 11 1 2 2 1 1 2 1 2 2 1 1 1 1 10.5 3.9 62
5 11 1 2 2 1 2 1 1 2 2 2 1 1 1 8.9 2.9 67
6 6 2 2 2 1 2 1 1 2 2 2 2 1 2 11.9 2.2 81
7 15 1 2 2 1 1 2 1 2 2 2 2 1 2 8.75 4.5 48
8 6 .5 1 2 2 1 2 1 1 2 2 2 2 1 2 9.38 4.99 46
9 10 1 2 2 1 2 1 1 1 2 2 2 1 2 9 2.5 72
10 7 2 2 2 1 1 2 1 2 2 2 2 1 1 8.7 2.3 73
11 9 2 2 2 1 2 1 1 1 2 2 1 1 2 16.1 3.2 80
12 11 2 2 2 1 2 1 1 1 2 2 2 1 2 4 2.2 45
13 5 2 2 2 1 1 2 1 2 2 2 2 1 2 3.69 1.97 47
14 8 2 2 2 1 1 2 1 2 2 2 2 1 2 5.2 4.2 21
15 9 2 2 2 1 1 2 1 2 2 2 2 1 2 9.36 7.03 24
16 11 1 2 2 1 1 2 1 2 2 2 2 1 2 6 2.6 52
17 9 2 2 2 1 2 1 1 2 2 2 2 1 2 4.7 1.7 63
18 13 2 2 2 1 2 1 1 2 2 2 2 1 2 7.1 2.1 70
19 11 1 2 2 1 2 1 1 2 2 2 2 1 1 10.4 3.9 62.5
20 15 2 2 2 1 1 2 1 2 2 2 2 1 2 13.7 8.7 36
21 13 1 2 2 1 2 1 1 2 2 2 2 1 1 7.41 4.25 42
22 13 1 2 2 1 2 1 1 2 2 2 2 1 2 18.6 5.02 73
23 9 2 2 2 1 2 1 1 2 2 2 2 1 2 16.8 3 82
24 6 .5 2 2 2 1 2 1 1 1 2 2 2 1 1 5 3.2 36
25 7 2 2 2 1 2 1 1 1 2 2 2 1 2 3.9 2.3 41
26 12 1 2 2 1 1 2 1 2 2 2 1 1 1 7 5.4 22
27 13 2 2 2 1 2 2 2 2 2 2 2 2 2 7 2.5 64
28 8 2 2 2 1 2 1 1 1 2 2 2 1 2 3.9 2.4 38
29 5 .5 2 2 2 1 2 1 1 1 2 2 2 1 1 8 4.5 45
30 6 2 2 2 1 2 1 1 2 2 2 2 1 2 6.1 3.8 37
31 9 1 2 2 2 2 2 2 2 2 2 2 2 2 2.02 1.9 4
32 13 2 2 2 2 2 2 2 2 2 2 2 2 2 6.4 1.9 70
33 11 2 2 2 2 2 2 2 2 2 2 2 2 2 4.4 0.15 96
34 13 2 2 2 2 2 2 2 2 2 2 2 2 2 0.72 0.69 4
35 12 2 2 2 2 2 2 2 2 2 2 2 2 2 2.7 0.4 85
36 13 2 2 2 2 2 2 2 2 2 2 2 2 2 8.3 2.2 73
37 13 2 2 2 2 2 2 2 2 2 2 2 2 2 12.6 1.8 85
38 11 2 2 2 2 2 2 2 2 2 2 2 2 2 8.3 1.8 78
39 13 2 2 2 2 2 2 2 2 2 2 2 2 2 11.9 3.8 68
40 13 2 2 2 2 2 2 2 2 2 2 2 2 2 6.7 1.5 77
41 13 2 2 2 2 2 2 2 2 2 2 2 2 2 7.6 1.7 77
42 14 1 2 2 2 2 2 2 2 2 2 2 2 2 4.9 1.9 61
MASTER CHART
43 14 1 2 2 2 2 2 2 2 2 2 2 2 2 4.95 3.3 32
44 14 1 2 2 2 2 2 2 2 2 2 2 2 2 3.04 2.2 27
45 11 2 2 2 2 2 2 2 2 2 2 2 2 2 4.78 3.1 35
46 14 1 2 2 2 2 2 2 2 2 2 2 2 2 6.9 1.9 72
47 14 1 2 2 2 2 2 2 2 2 2 2 2 2 3.5 1.7 51
48 7 1 2 2 2 2 2 2 2 2 2 2 2 2 5.8 1.04 82
49 12 1 2 2 2 2 2 2 2 2 2 2 2 2 6.8 1.9 72
50 9 2 2 2 1 2 1 2 2 2 2 2 1 2 12.37 6.73 45
51 9 2 2 2 2 2 2 2 2 2 2 2 2 2 6.75 3.97 41
52 8 1 2 2 2 2 2 2 2 2 2 2 2 2 11.22 5.3 52.7
53 13 1 2 2 2 2 2 2 2 2 2 2 2 2 5.84 3.97 32
54 8 1 2 2 2 2 2 2 2 2 2 2 2 2 10 3.58 64.2
55 11 1 2 2 2 2 2 2 2 2 2 2 2 2 9.28 3.49 62.3
56 11 1 2 2 2 2 2 2 2 2 2 2 2 2 12.2 4 67
57 9 1 2 2 2 2 2 2 2 2 2 2 2 2 7.79 5.41 30.5
58 12 1 2 2 2 2 2 2 2 2 2 2 2 2 9.48 2.97 68.6
59 12 1 2 2 2 2 2 2 2 2 2 2 2 2 8.76 3.24 63
60 12 1 2 2 2 2 2 2 2 2 2 2 2 2 7.59 5.17 31.8
61 10 1 2 2 2 2 2 2 2 2 2 2 2 2 7.95 3.12 60.7
62 11 1 2 2 2 2 2 2 2 2 2 2 2 2 7.22 2.6 63.9
63 9 1 2 2 2 2 2 2 2 2 2 2 2 2 12.01 3.24 73
64 10 1 2 2 2 2 2 2 2 2 2 2 2 2 7.74 6.33 18.2
65 13 1 2 2 2 2 2 2 2 2 2 2 2 2 10.83 4.96 54.2
66 12 1 2 2 2 2 2 2 2 2 2 2 2 2 11.56 2.74 76.2
